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Multi-target drugs have greatly attracted the attention and interest in drug 
discovery.  Efforts that explore experimental and in-silico methods have been and 
are  being made in search for the novel multi-target agents. As part of the 
collective efforts for developing the tools to facilitate discovery multi-target 
agents, I firstly participated in the updated the Kinetics database of bio-molecular 
interactions (KDBI) and the Therapeutic targets database (TTD). The information 
in the two databases can offer informative data in multi-target drug discovery.  
 
Virtual screening (VS) is an increasingly used approach in the search for novel 
lead compounds. It is capable of providing valuable contributions in hit and lead 
compounds discovery.  It has been intensively explored and various software tools 
have been developed for the application of VS.  It would be very interesting to 
apply VS tools for the discovery of multi-target agents. However, many of the 
conventional VS tools encounter the issues of the insufficient coverage of 
compound diversity, high false positive, high false negative prediction and lower 
speed in screening large libraries. These issues would hinder the practical 
applications of conventional VS approaches in search of multi-target agents. 
Therefore, in order to identify multi-target agents that are more sparsely 
distributed in the chemical space than single-target agents, it is important to 
address these issues and develop the methods that are capable of searching large 




In this work, I explored a machine learning method, support vector machines 
(SVM), to develop the combinatorial SVM (COMBI-SVM) VS tool for searching 
dual-target agents for the treatment of cancers and major depression. COMBI-
SVMs models were preliminarily tested for searching dual-inhibitors of 4 
combinations (EGFR-FGFR, EGFR-Src, VEGFR-Lck, and Src-Lck) of the 5 
anticancer kinase targets (EGFR, VEGFR, Src, FGFR, Lck). COMBI-SVMs 
produced comparable dual-inhibitor yields and significantly lower false-hit rates 
for MDDR and PubChem dataset. There has been underpinning interest in 
discovery and developing selective multi-target serotonin reuptake inhibitors 
(SRIs) that can enhance antidepressant efficacy (1). The preliminary tests with the 
4 kinase dual-inhibitors showed promising results and this encouraged me to 
develop and test COMBI-SVMs for VS  multi-target serotonin reuptake inhibitors 
of 7 target pairs (serotonin transporter paired with noradrenaline transporter, H3 
receptor, 5-HT1A receptor, 5-HT1B receptor, 5-HT2C receptor, Melanocortin 4 
receptor and Neurokinin 1 receptor respectively) from large compound libraries. 
COMBI-SVMs showed moderate to good target selectivity in misidentifying 
individual-target inhibitors of the same target pair and inhibitors of the other 
target six pairs as dual-inhibitors; COMBI-SVMs also presented low dual-
inhibitor false-hit rates in screening large compound databases MDDR and 
PubChem. Compared to the other three VS methods (similarity searching, k-NN 
and PNN), it produced comparable dual-inhibitor yields, similar to or slightly 
better target selectivity, and slightly to or substantially lower false-hit rate in 
screening MDDR compounds.  
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Chapter 1 Introduction 
Considerable efforts have been put into drug design; however, the number of 
successful drugs did not increase appreciably during the past decade. Recent 
evidence suggests that the main causes of failure of compounds in the clinic are 
lack of efficacy and poor safety.  Agents that modulate multiple targets 
simultaneously have the potential to enhance efficacy or improve safety relative to 
drugs that modulate only a single target. As a result, multi-target agents have 
been gaining increasing interest of researchers and drug discovery teams. To 
assist the research of multi-target discovery, I participated in the further 
development of two pharmainformatics databases, i.e., the update of KDBI and 
BIDD. As a complementary approach to the traditional chemical and biological 
methods, virtual screening has aroused increasing attention in the 
pharmaceutical industry as a productive and cost-effective technology (2). 
Various computational screening tools, such as docking, quantitative structure 
activity relationship (QSAR), support vector machines (SVM), k-NN, PNN etc, are 
being developed and refined to effectively employ fast screening methods to yield 
potent lead hits. In my work, the combinatorial SVM (COMBI-SVM) virtual 
screening (VS) tool was developed for searching multi-target agents. This method 
was firstly tested with four anticancer kinase target pairs and then was applied to 
seven antidepressants target pairs. Compared with the other three VS methods, 
i.e., similarity searching, k-NN and PNN, COMBI-SVM produced comparable 
dual-inhibitor yields, similar to or slightly better target selectivity, and slightly to 
or substantially lower false-hit rate in screening MDDR compounds. 





The following sections present a brief introduction to development of 
pharmainformatics databases (Section 1.1), an overview of methods in virtual 
screening (Section 1.2) and in-silico approaches to multi-target drug discovery 
(Section 1.3). In addition, the outline of this thesis (Section 1.4) is introduced. 
 
1.1 Pharmainformatics Database Development and Updates 
With the exponential increase in pharma-information, it is becoming increasingly 
necessary and important to collect and curate the information to provide 
informative sources to effectively  assist the studies of disease mechanisms and 
the discovery of new drugs. Pharmainformatics databases can provide up-to-date 
information and data that relate to disease mechanism studies, pharmaceutical 
research and drug development. They offer various types of information for a 
number of interdisciplinary areas such as bioinformatics, chemoinformatics, drug 
data, bioactive compound data, interaction and kinetics data, in- silico ADME-
Tox prediction and molecular modeling.  
 
The process of a database construction consists of two major steps. The first step 
is data collection and quality control. The quantity and quality of the data are 
decisive to the usefulness and popularity of a database. The second step involves 
database interface design and maintenance. Well-designed databases usually share 
the following qualities: informative with a clear presentation; user-friendly with 
easy manipulation; fast and accurate search within the database; Continuous 





updates with new information, data and other features. Additional qualities 
include data download, inter links to other related databases and data processing 
functions for the personalized data.  
 
In this work, I participated in the update of the Kinetics database of  bio-
molecular interactions (KDBI) http://xin.cz3.nus.edu.sg/group/kdbi/kdbi.asp (3) 
and the Therapeutic targets database (TTD) http://bidd.nus.edu.sg/group/ttd/ (4).  
 
KDBI stores the kinetic information of bio-molecular interactions. This 
information is essential for quantitative studies of the interactions between bio-
molecules of a given bio-system (3). Numerous  improvements  and  updates  
have  been  added to  KDBI,  including  new  ways  to  access  data  by pathway 
and molecule names, data file in System Biology  Markup  Language (SBML)  
format. It can accommodate the increasing data demand in quantitative system 
biology studies which play an important role in understanding the mechanisms 
underlying many complex diseases.   
 
TTD has been developed to provide comprehensive information about the known 
targets and the corresponding approved, clinical trial and investigative drugs. 
Since its last update in 2010, major improvements and updates have been made to 
TTD. These updates include a significant increase of data content, target 
validation information and quantitative structure activity relationship (QSAR) 
models.  





1.2 Introduction to Virtual Screening in Drug Discovery 
Traditionally, the progress in drug discovery has been made by a combination of 
random screening and rational design (5). Given the mounting competiveness of 
pharmaceutical industry, high throughput screening (HTS) has become a key tool 
in many pharmaceutical companies for its ability to test vast number of 
compounds quickly and efficiently. However, HTS offers no guarantee of success 
and over-reliance on random HTS are showing apparent problems. Additionally, 
establishing a robust assay is very costly: a single HTS programme without assay 
development could still cost approximately US $75,000 (6). Moreover, collections 
of synthesized compounds or natural products can only represent a limited space 
in the entire drug-like chemical space. The typical screening collection of a large 
pharmaceutical company is of the order of a few million compounds at most. This 
is a tiny fraction of the huge chemical space (7, 8), which is many orders of 
magnitude larger than this, even if only drug-like compounds are considered (9). 
Given these caveats, it is worth evaluating other technologies that may 
complement HTS assay and synthesis. The term 'virtual screening' first came into 
being in 1997; it has been used to describe a process of computationally analyzing 
large compound collections in order to prioritize compounds for synthesis or 
assay. During the last decade, a broad range of computational techniques have 
been applied to search for novel bioactive compounds for many targets. VS 
method does not require the physically synthesized compound libraries such 
greatly recedes the cost. This also potentially extends the exploration of the 
chemical space outside the in-house compound pools. There are around 10 million 





commercially available compounds that can be exploited with the VS approach. 
On top of it, virtual combinatorial libraries contain at least 1 million-fold larger 
libraries than those available for HTS. This adds a new dimension to the VS 
search space (Figure 1-1). 
 
Figure 1-1 Typical numbers of compounds available in the chemical space 
 
 Based on the requirement of either the structure of a target or its ligands, virtual 
screening methods can be often classified into structure-based virtual screening 
(SBVS) and ligand-based virtual screening (LBVS) (10). SBVS consists of the 
virtual docking of candidate ligands into a protein target followed by the 
estimation of the probability of the high affinity binding between them calculated 
by a scoring function (11, 12). LBVS methods, such as pharmacophore methods 
(13) and chemical similarity analysis methods (14), require the ligand structure 
information, they focus on discoverying the new drug hits by analyzing the 
physical and chemical similarities of known compound pools by computational 





means.   
Figure 1-2 shows the general procedure used in SBVS and LBVS.  
 
Figure 1-2 General procedure used in SBVS and LBVS (adopted from Rafael V.C. 
et al(10)). 
 





1.2.1 Structure-based and ligand based virtual screening  
Structure-based virtual screening (SBVS) starts with a 3-D structure of a target 
protein and a database of the 3-D structures of ligands as the screening pool. It is 
usually applied when the 3D structure of a protein target, derived either from 
experimental data (X-ray or NMR spectroscopy) or from homology modeling, is 
available. SBVS procedure consists of docking and scoring. The docking 
algorithms (11, 12) are designed to predict the ligand conformation and 
orientation within the targeted active site of the target. The scoring methods  are  
empirically or semi-empirically derived to attempt (13) to estimate the binding 
tightness of the ligand and the protein in bound complexes.  Docking and scoring 
algorithms are combined to detect the compounds with higher affinity against a 
target by predicting their binding mode (by docking) and affinity (by scoring), and 
retrieving those with the highest scores. To date, more than 60 docking programs 
and 30 scoring functions have been reported (14, 15). The major drawback with 
SBVS is the unavailability of appropriate scoring functions to differentiate 
between correct and incorrect poses of bound ligands and identifying false 
negative and positive hits. Some of the key challenges encountered by SBVS 
include the appropriate treatment of ionization,  tautomerization  of  ligand  and  
protein  residues, target/ligand flexibility, choice of force fields, solvation effects,  
dielectric  constants,  exploration  of  multiple binding modes and, most 
importantly, the approximations in the scoring functions that lead to false-
positives and missed true-hits. Moreover, most docking algorithms and scoring 
functions are tuned towards high throughput, which requires a compromise 





between the speed and accuracy of binding mode and energy prediction. Despite 
the successful drug discovery cases, currently there has not been a single docking 
program that outperforms all others with regard to either docking accuracy or hit 
enrichment. The hit enrichment is defined as the fraction of true active 
compounds in, for example, the upper 1% of the ranked VS hit list compared with 
the average fraction of active compounds in the search space. The performance of 
a docking program is difficult to evaluate in advance, and depends on the nature 
and quality of the target structure (14-16). Despite all optimization efforts, the 
currently available scoring functions do not provide reliable estimates of free 
binding energies, and are not able to rank compounds according to affinity (15, 
17). The published comparisons of docking programs have been critically 
reviewed (18-20).  
 
Ligand-based virtual screening (LBVS) does not require the target structure 
information. Instead, it uses the structure(s) of one or more active compounds as 
template(s) to indentify a new compound pool by chemical and physical 
similarities. In general, the application of LBVS methods employ the 
computational descriptors of molecular structure, properties, or pharmacophore 
features and analyze relationships between the active compounds and test 
compounds. Complex descriptors are designed to detect similarities in molecular 
shape and shape-related properties in order to find new hits. LBVS is 
computationally efficient and can scan very large databases in reasonably short 
time. As a result, it is often applied to sequentially filter large compound sets 





before more complex tools are applied. A considerable number of types of 
different methods have been reported with literally thousands of different 
descriptors. These descriptors are derived from the 2D or 3D distribution of 
atomic properties of the known compounds, or from the presence of specific 
structural elements. Many methods designed for the comparison of the similarity 
of compounds based on these descriptors. Shape comparison (21) and 
pharmacophore searches are frequently-used long-established techniques (22, 23). 
Other methods apply molecular fields to define the similarity of structures (24, 
25). When large sets of active and inactive compounds are known, machine 
learning techniques, such as artificial neural nets, decision trees, support vector 
machines or Bayesian classifiers, can be used to train models that can distinguish 
active from inactive compounds based on their specific structural features. 
Comprehensive overviews of ligand-based VS have been presented in a number 
of reviews (26, 27). Table 1-2, 1-3, 1-4, 1-5 show the performances of some 
frequently applied SBVS and LBVS methods for identifying inhibitors, agonists 
and substrates of proteins of pharmaceutical relevance. 
 
1.2.2 Conventional approaches of virtual screening methods 
Conventional VS approaches such as docking have been widely studied for 
facilitating lead discovery against individual targets (28-30). Among the various  
conventional methods, molecular docking (31), pharmacophore (32), structure-
activity relationship (SAR) and quantitative structure activity relationship 





(QSAR) (33), similarity searching (34) have been extensively used for searching 
and designing active compounds against individual targets.  
 
1.2.3 Machine learning methods for virtual screening 
Machine learning classification methods use binary, categorical or continuous 
descriptors to estimate the probability of a molecule to be active on the basis of 
learning sets. Machine learning methods can be classified as supervised or 
unsupervised. If instances are given with known labels then the learning is called 
supervised (Table 1-1) whereas instances are unlabeled in unsupervised learning.  
Data in standard descriptor format 
Case Feature 1 Feature 2 … Feature n Class 
1 Charge: 0 Benzene ring: 1   Nitrogen: 2 Active 
2 Charge:+1 Benzene ring: 2   Nitrogen: 3 Active 
3 Charge:-1 Benzene ring: 3   Nitrogen: 1 Inactive 
…         … 
  Table 1-1 Instances of supervised machine learning methods  
 
Commonly utilized supervised machine learning methods include Support Vector 
Machine (SVM), Artificial Neural Network, Decision tree learning, Inductive 
logic programming, Boosting, Gaussian process regression etc. Unsupervised 
machine learning with the unlabeled training aims at finding the internal 
organization of the data. Examples of unsupervised machine learning include 
Clustering, Adaptive Resonance Theory, and Self Organized Map.  
 
Compared to SBVS and other LBVS methods such as QSAR, pharmacophore and 
clustering methods (35-42), machine learning methods are more capable of 





working with a more diverse spectrum of compounds and more complex 
structure-activity relationships. This is because machine learning methods apply 
complex nonlinear mappings from molecular descriptors to activity classes 
without restriction on structural frameworks, and they do not require prior 
knowledge of relevant molecular descriptors and functional form of structure-
activity relationships (43-47). Additionally, machine learning methods can 
overcome several problems that have obstructed some conventional virtual 
screening tools (28, 44). These obstacles include the extensiveness and 
discreteness natures of the chemical space, the absence of protein target structures 
(current statistics shows that the known protein sequences (~1,000,000)(48) vastly 
outnumber the available protein structures (~20,000)(49)), complexity and 
flexibility of target structures, limited diversity caused by the biased training 
molecules, and difficulties in computing binding affinity and solvation effects.  
 
The performance report of machine learning methods in screening 
pharmacodynamically active compounds from libraries of >25,000 compounds is 
summarized in Table 1-2. These reported studies (50-57) primarily focused on the 
prediction of compounds that inhibit, antagonize, block, agonize, or activate 
specific therapeutic target proteins. The majority of the reported screening tasks 
by machine learning methods are found to demonstrate good performances. The 
yields, hit rates, and enrichment factors of machine learning methods are in the 
range of 50%~94%, 10%~98%, and 30~108 respectively. 
 





Tentative comparisons are presented in Table 1-3, Table 1-4 and Table 1-5 for 
the reported performances of structure-based VS methods and two classes of 
ligand-based VS methods, pharmacophore and clustering. The majority of the 
yields, hit rates, and enrichment factors lay in the range of 7%~95%, 1%~32%, 
and 5~1189 for structure-based, 11%~76%, ~0.33%, and 3~41 for 
pharmacophore, and 20%~63%, 2%~10%, and 6~54 for clustering methods 
respectively. Therefore, the general performance of machine learning methods 
appears to be comparable to or in some cases better than the reported 
performances of the conventional VS studies such as pharmacophore and 
clustering methods. In screening extremely-large libraries, the reported yields, hit-
rates and enrichment factors of machine learning VS tools are in the range of 
55%~81%, 0.2%~0.7% and 110~795 respectively, compared to those of 
62%~95%, 0.65%~35% and 20~1,200 by structure-based VS tools. The reported 
hit-rates of some machine learning VS tools are comparable to those of structure-
based VS tools in screening libraries of ~98,000 compounds, but their enrichment 
factors are substantially smaller. Therefore, while exhibiting equally good yield, 
in screening extremely-large (≥1 million) and large (130,000~400,000) libraries, 
the currently developed machine learning VS tools appear to show lower hit-rates 
and, in some cases, lower enrichment factors than the best performing structure-
based VS tools.  
 
The machine learning methods employed in this work are SVM, Probabilistic 
Neural Network (PNN) and k nearest neighbor (k-NN). They are explained below 





in subsequent sub sections. For a comparative study, Tanimoto similarity 
searching method is also introduced. 
 
 




Table 1-2 Performance of machine learning methods in virtual screening test for identifying inhibitors, agonists and substrates of proteins 
of pharmaceutical relevance. The relevant literature references are given in the method column. 
Screening 
task 

































































98,435 536 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 232 43.4% 23.7% 43.1 
ECFP4 100/4000 984 1% 365 68.1% 37.2% 67.7 
SVM-
RBF (47)  
Pipeline pilot 100/4000 984 1% 240 44.7% 24.4% 44.5 
Thrombin 
inhibitors 

















98,435 703 CKD 
(47)  
Pipeline pilot 100/4000 984 1% 435 61.9% 44.4% 61.7 
ECFP4 100/4000 984 1% 603 85.8% 61.5% 85.5 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 381 54.2% 38.9% 54.0 
Protease 
inhibitors 









LMNB 19 16% 1% 14.5 



































98,435 852 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 480 56.4% 49.0% 56.3 
ECFP4 100/4000 984 1% 680 79.8% 69.4% 79.8 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 529 62.1% 54.0% 62.1 
5HT1A 
antagonists 









98,435 727 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 268 36.9% 27.3% 36.9 
ECFP4 100/4000 984 1% 426 58.6% 43.5% 58.7 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 319 43.9% 32.6% 44.0 
5HT reuptake 
inhibitors 





100/400 5125 5% 65 25% 1.2% 4.7 
 
98,435 259 CKD 
(47)  
Pipeline pilot 100/4000 984 1% 131 50.7% 13.4% 51.5 
ECFP4 100/4000 984 1% 194 75.6% 19.7% 75.9 
SVM-
RBF (47)  
Pipeline pilot 100/4000 984 1% 137 52.9% 14.0% 53.8 
D2 
antagonists 









98,435 295 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 132 44.7% 13.5% 44.9 
ECFP4 100/4000 984 1% 219 74.4% 22.4% 74.7 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 137 46.4% 14.0% 53.8 
















98,435 1030 CKD 
(47)  
Pipeline pilot 100/4000 984 1% 842 81.8% 86.0% 81.9 
ECFP4 100/4000 984 1% 960 93.2% 98.0% 93.3 
SVM-
RBF (47) 













98,435 843 CKD 
(47)  
Pipeline pilot 100/4000 984 1% 393 46.6% 40.1% 46.6 
ECFP4 100/4000 984 1% 593 70.4% 60.6% 70.4 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 384 45.6% 39.2% 45.6 
Substance P 
antagonists 









98,435 1146 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 705 61.5% 71.9% 61.5 
ECFP4 100/4000 984 1% 942 82.2% 96.1% 82.2 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 509 44.4% 51.9% 44.4 
HIV protease 
inhibitors 









98,435 650 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 436 67.1% 44.5% 67.4 
ECFP4 100/4000 984 1% 574 88.3% 58.6% 88.7 
SVM-
RBF (47) 
Pipeline pilot 100/4000 984 1% 355 54.6% 36.2% 54.9 
Protein kinase 
C inhibitors 









98,435 353 CKD 
(47)  
Pipeline pilot 100/4000 984 1% 238 67.3% 24.2% 67.3 
ECFP4 100/4000 984 1% 291 82.5% 29.7% 82.5 







Pipeline pilot 100/4000 984 1% 206 58.3% 21.0% 58.3 
MAO 
inhibitors 
101,437 1166 BKD 
(64) 










98,435 748 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 467 62.4% 47.4% 62.4 




98,435 1211 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 604 49.9% 61.4% 49.9 




98,435 277 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 192 69.3% 19.5% 69.7 




98,435 782 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 436 55.8% 44.3% 56.1 




98,435 419 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 238 56.9% 24.2% 56.3 
ECFP4 100/4000 984 1% 337 80.4% 34.2% 79.6 
Aromatase 
inhibitors 
98,435 413 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 284 68.7% 28.8% 68.6 
ECFP4 100/4000 984 1% 389 94.1% 39.5% 94.0 
Phospholipase 
A2 inhibitors 
98,435 604 CKD 
(47) 
Pipeline pilot 100/4000 984 1% 297 49.2% 30.2% 49.5 
ECFP4 100/4000 984 1% 447 74.0% 45.4% 74.5 
CDK2 
inhibitors 



















































125/5035 506 2% 20 80% 3.9% 39.5 
 
 
BKD – binary kernel discrimination; CKD – Continuous kernel discrimination; DS – decision tree; LMNB – laplacian modified naive Bayesian; SVM – support vector 
machine; DRAGON – (an application for the calculation of molecular descriptors); AR – androgen receptor; PDE 5 – phosphodiesterase type 5; FXa – factor Xa;  
CDK2 – cyclin-dependent kinase 2; MAO – mono amino oxidase; HIV – human immunodeficiency virus; COX – cycloocygenase; 
 





Table 1-3  Performance of docking methods in virtual screening test for identifying inhibitors, agonists and substrates of proteins of 
pharmaceutical relevance; the relevant literature references are given in the method column. 
Screening 
task 































2M 630 AUTODOCK + 
pre-docking RO5 
and EA screen 
(66) 
60,000 Binding 
energy <   
-10.5 
kcal/mol 





1.2M 355 DOCK+ pre-
docking chemical 
group screen (67)  
13,711 DOCK 
scores <    
-35 















400K >4 DOCK4 + H-
bond and hinge 
segment screen 
(68)  







250K >14 ICM VLS module 






















889 0.38% 127 N/A 14.3
% 
N/A 
141K 10 GOLD + elements 
and chemical 
group screen (71) 
<141K Top-2% <2820 <2.5% 8 80% <0.28
% 
39.4 







206,876 >1 DOCK3.5 + non-
peptidic screen 
(72) 
<206,876 Top-500 35 0.017% 1 N/A 2.9% N/A 
HIV-1 protease 
inhibitors 


















UPA inhibitors 141K 10 GOLD + elements 
and chemical 
group screen (71) 











22,950 Top-300 300 0.21% 38 N/A N/A N/A 
Thrombin 
inhibitors 




<141K Top-2% <2820 <2.5% 3 30% <0.11
% 
15.5 
133.8K 760 FlexX + 
Similarity (74) 







135K 165 DOCK3.5.54 





1350 1% 47 25% 3.4% 27.8 
DOCK3.5.54 









135K 356 DOCK3.5.54 (75) 135K Top-1% 
of 
125.5K 
1255 0.74% 3 0.8% 0.24
% 
~1 
















135K 185 DOCK3.5.54 (75) 135K Top-1% 
of 54K 
docked 





135K 25 DOCK3.5.54 (75) 135K Top-1% 
of 123K 
docked 




135K 356 DOCK3.5.54 














4500 3.3% 5 1.4% 0.11
% 
<1 
133.8K 59 FlexX + 
Similarity (74) 






135K 637 DOCK3.5.54 





770 0.57% 49 7.7% 6.4% 13.6 
DOCK3.5.54 









133.8K 1016 FlexX + 
Similarity (74) 
<133.8K Top-1% 1338 1% 35 3.4% 2.6% 3.4 





Table 1-4 Performance of pharmacophore methods in virtual screening test for identifying inhibitors, agonists and substrates of proteins of 
pharmaceutical relevance. The relevant literature references are given in the method column. 
Screening 
task 
Compounds screened Method and 
reference of 
reported study 

























3.8M 55 Structure-based 
pharmacophore (77) 




















Table 1-5 Performance of clustering methods in virtual screening test for identifying inhibitors, agonists and substrates of proteins of 
pharmaceutical relevance; the relevant literature references are given in the method column. 
Screening 
task 
Compounds screened Method and reference of 
reported study 



























NIPALSTREE (40) 8174 2.4% 188 38.4% 2.3% 16.2 
Hierachical k-means + 
NIPALSTREE disjunction 
(40) 
12240 3.6% 306 62.4% 2.5% 17.6 
Hierachical k-means + 
NIPALSTREE conjunction 
(40) 
1662 0.48% 128 26.1% 7.7% 54 
COX 
inhibitors 
344.5K 1556 Hierachical k-means (40) 15322 4.4% 761 48.9% 5.0% 11 
NIPALSTREE (40) 22321 6.5% 625 40.2% 2.8% 6.16 
Hierachical k-means + 
NIPALSTREE disjunction 
(40) 
33793 9.8% 980 63.0% 2.9% 6.42 
Hierachical k-means + 
NIPALSTREE conjunction 
(40) 
3980 1.2% 406 26.1% 10.2% 22.6 
Adrenoceptor 
ligand 
344.5K 542 Hierachical k-means (40) 21285 6.2% 298 55.0% 1.4% 8.99 
NIPALSTREE (40) 28125 8.2% 270 49.8% 0.96% 6.14 
Hierachical k-means + 
NIPALSTREE disjunction 
(40) 
42365 12.3% 394 72.7% 0.93% 5.93 





Hierachical k-means + 
NIPALSTREE conjunction 
(40) 




344.5K 91 Hierachical k-means (40) 3750 1.1% 27 29.7% 0.72% 27..3 
NIPALSTREE (40) 3469 1.0% 17 18.7% 0.49% 18.7 
Hierachical k-means + 
NIPALSTREE disjunction 
(40) 
7317 2.1% 30 33.0% 0.41% 15.6 
Hierachical k-means + 
NIPALSTREE conjunction 
(40) 




344.5K 478 Hierachical k-means (40) 10000 2.9% 110 23% 1.1% 7.97 
NIPALSTREE (40) 17143 5.0% 84 17.6% 0.49% 3.51 
Hierachical k-means + 
NIPALSTREE disjunction 
(40) 
24265 7.0% 165 34.5% 0.68% 4.86 
Hierachical k-means + 
NIPALSTREE conjunction 
(40) 










1.3 In-silico Approaches to Multi-target Drug Discovery 
1.3.1 Introduction  
Therapeutic agents directed at an individual target frequently show reduced 
efficacies, undesired safety profiles and drug resistances due to network 
robustness (78), redundancy (79), crosstalk (80), compensatory and neutralizing 
actions (81), anti-target and counter-target activities (82), and on-target and off-
target toxicities (83).  It is being increasingly recognized that a balanced 
modulation of several targets can provide a superior therapeutic effect and side 
effect profile compared to the modulation of a single selective ligand. It is not 
surprising that the search of multi-target agents is constantly attracting the 
attention of increasing number of drug discoverers (1, 84, 85).  
 
With the extensive exploration of in sillico tools in pharmaceutical research, these 
computational approaches can greatly assist and complement the traditional 
biological and chemical methods in the discovery of new drug hits and leads. This 
is especially helpful with the increasingly abundant pharmainformatics data being 
published and shared across the globe which offers a strong foundation for in-
sillico approaches.   
 
Some of these methods have recently been applied for searching and designing 
multi-target agents that are more sparsely distributed in the chemical space than 
agents against a single target. Figure 1-3, Figure 1-4, Figure 1-5, and Figure 1-6 
summarize the schemes of using molecular docking, combined molecular docking 





and pharmacophore, framework combination, and fragment-based approaches for 
multi-target drug discovery using dual-inhibitor discovery as examples. These 
methods can be categorized into combinatorial approaches and fragment–based 
approaches. Combinatorial approaches (Figure 1-3 and Figure 1-4) are firstly 
straightforwardly conducted as parallel search against each individual targets and 
then the virtual hits that interact with individual multiple targets are detected as 
multi-target agents. Combinatorial approaches are practically useful when the 
retrieval rates against individual targets are sufficiently high and the false-hit rates 
are sufficiently low. High retrieval rates can compensate for the reduced 
collective retrieval rates (if the retrieval rate against individual target is 
50%~70%, the collective retrieval rate for multi-target agents against two targets 
may be statistically reduced to 25%~49%). Low false-hit rates are needed for high 
enrichment in searching multi-target agents that are significantly fewer in 
numbers and more sparsely distributed in the chemical space than agents against a 
single  target.  
 





             
Figure 1-3 Molecular docking strategy for multi-target inhibitor discovery 
    
Figure 1-4 Combined pharmacophore and molecular docking strategy of multi-
target inhibitor discovery 
 
 





             







                   
Figure 1-6 Illustration of fragment-based approach to multi-target drug discovery 





Fragment-based approaches (Figure 1-5 and Figure 1-6) are designed to combine 
multiple elements of structural frameworks or multiple fragments that bind to 
each individual target to produce compounds that bind to multiple targets. They 
have been introduced as tools for the design of multi-target agents (86). In one 
approach, molecular fragment libraries are searched to find the fragments with 
certain level of activities against selected multiple targets, and the identified 
fragments are further optimized into more potent bigger-sized multi-target active 
agents (86). The other approach aims at the analysis of the structure-activity 
relationships against individual targets  for the search of molecular fragments and 
essential binding features which are either combined or incorporated into active 
agents against selected multiple targets (86). However, fragment combinations 
often produce larger and non-drug like molecules with more complex structures. 
Drug-like features may be retained if the degree of framework overlap is 
maximized and the size of the selected fragments is minimized. Targets sharing a 
conserved binding makes it relatively more  easily for the optimizing fragments 
with weak multiple activities into potent multi-target drug-like agents (87). But 
with the increased similarities among binding sites, it is becoming more difficult 
to improve and adequately balance the high binding affinities for acceptable in-
vivo efficacy and safety. One way to resolve this problem relies on synergistic 
targets for their modest activities at one or more of the relevant targets. This may 
still produce similar or better in-vivo effects compared with higher-affinity target-
selective compounds (88). 
 





Multi-target QSAR models for identification of multi-target agents (89) and active 
agents against multiple bacterial (90), fungal (91, 92), and viral (90), species have 
been developed. These models incorporate multi-target or species variations of 
binding-site features into the multi-target dependent molecular descriptors or 
species-dependent molecular descriptors, and stochastic Markov drug-binding 
process models. They can achieve high retrieval rates of 72%~85% and 
moderately low false-hit rates of 15%~28%. However, the application of multi-
target QSAR models may be limited by the inadequate number of drug data for 
some of the targets or species. Moreover, the molecular size of the testing drugs is 
limited within a certain range for accurate computation of multi-target dependent 
or species-dependent molecular descriptors. This in some cases may also affect 
the development of multi-target QSAR models (92). 
 
1.3.2 Machine learning methods for searching multi-target agents 
Cancer is known to be a fatal disorder which has been threatening lives of 
millions of people per year. In the last decades , untangling the molecular 
mechanisms underlying malignant transformation have been the center of efforts 
in basic and clinical cancer research to discover molecules that play a crucial and 
specific role in tumor progression (93).  Protein kinases play important roles in 
regulating most cellular functions: proliferation/cell cycle, cell metabolism, 
survival/apoptosis, DNA damage repair, cell motility, response to the 
microenvironment. Therefore, it is no surprise that they are often themselves 
oncogenes. Kinases take the second most popular drug target class in the 





pharmaceutical and biotech industries, after G-protein-coupled receptors (94). 
However, clinical experience confronts us with the fact that many tumors are 
multi-factorial  and  interlinked by more  than  one  signaling  pathway which 
makes  the  inhibition  of  a  single  molecule  not  sufficient to interfere 
efficiently with disease progression. For these reasons, monotherapy by means of 
single-target drugs  may  need  to  be  reassessed  in  favor  of  a  multi- target 
approach. In this work, I examined a SVM based combinatorial machine learning 
method COMBI-SVM for its performance for detecting multi-target kinase 
inhibitors for 4 kinase target pairs, i.e., EGFR-FGFR,VEGFR-Lck, and Src-Lck. 
This is a preliminary test for the performances of COMBI-SVM in searching 
multi-target agents. 
 
Major depression is an enervating and recurrent disorder. It has become prevailing 
due to the fastened pace and enhanced stress levels in the modern societies. It 
affects patients with a substantial lifetime risk. A primary anti-depression strategy 
is to inhibit monoamine oxidase; Second-generation drugs launched in the 1980s 
and 1990s, such as the selective serotonin reuptake inhibitors (SSRI) and the 
mixed serotonin/noradrenaline reuptake inhibitors (SNRI). They present the 
dominant treatment strategy for major depression (95). However, single-target 
drugs (78, 85) frequently encounter the drug resistance problems caused by the 
network robustness (78), redundancy (79), crosstalk (80), compensatory and 
neutralizing actions (81), anti-target and counter-target activities (82), and on-
target and off-target toxicities (83). Multi-target drugs are particularly useful for 





solving these drug resistance problems. After the previous performance tests of 
COMBI-SVM in dual kinase inhibitors, I applied this approach to study the dual 
inhibitor SSRIs: SNRIs, dual serotonin reuptake inhibitor (SRI) / 5-HT1A receptor 
antagonists, dual SRI/ 5HT1B receptor antagonists, dual SRI/ H3 histamine 
receptor antagonists, dual SRI/5-HT2C receptor antagonists, dual 
SRI/Melanocortin 4 receptor antagonists, dual SRI/neurokinin 1 receptor 
antagonists.  Figure 1-7 shows the work flow for detecting multi-target agents by 
machine learning (ML) methods. 
 
 Figure 1-7 Work flow for detecting multi-target agents by machine learning (ML) 
methods; Structure-activity data are collected by literature mining. Then the ML 
method is applied to build a screening model which will be used to scan the 
compound database (e.g. PubChem); After the screening, positive dual-inhibitors 
will be selected for further synthesis and test. If they prove to have promising 





pharmacological profiles, they can be used into the training data for new 
predictions.  
1.4 Objectives and Outline  
Over all, I want to achieve four major objectives. 
1. To update and construct pharmainformatics databases to provide resourceful 
and informative platforms for researchers in various bio-and chemo-informatics. 
2. To test combinatorial machine learning methods for virtual screening of multi-
target agents for cancer treatment involving kinase targets EGFR, FGFR, Src, Lck 
and VEGFR. 
3. To apply combinatorial machine learning methods for virtual screening of 
Selective multi-target serotonin reuptake inhibitors. 
4. To compare the virtual screening performances of the machine learning 
methods SVM, k-NN, PNN and similarity searching in search of multi-target 
agents. 
 
In summary, this work aims at contributing to the current multi-target strategy in 
novel drug hits and leads discovery. This study employs two approaches to reach 
this goal. The first approach targets at optimizing the benefit of the increasingly 
abundant pharmaceutical data information. Pharmainformatics database is an 
efficient and resourceful means to achieve this goal. They dramatically accelerate 
the accumulation of data thus enhance the opportunity in new discoveries. A 
collective pharmaceutical data and discoveries have been presented online in the 





past ten years. These valuable data would benefit the discovery of multi-target 
agents. Additionally, combinatorial virtual screening methods can also assist the 
discovery of novel multi-target anticancer and antidepressant agents.  
This work is presented in the following manner. Chapter 1 firstly introduces the 
development of pharmainformatic databases and the different approaches in 
virtual screening. Secondly, it describes the ML approaches for multi-target 
discovery.  
 
In Chapter 2, methods used in this work are described. It introduces the data 
collection and processing before the application of VS tools. Theoretical 
backgrounds of machine learning methods discussed in the work are provided. VS 
model validation and performance measurements are described in details. 
 
Chapter 3 elaborates the updates and development work of two 
pharmainformatics databases, i.e. Kinetic database of bio-molecular interactions 
(KDBI) and Therapeutic targets database (TTD). 
 
Chapter 4 describes the preliminary tests with 4 kinase target pairs of 
combinatorial SVM (COMB-SVM) and Chapter 5 elaborates the studies and 
application of COMBI-SVM as virtual screening tools for multi-target 
antidepressants agents. 
 





At last, Chapter 6 summarizes the findings of this work and discusses the 
limitations. 




Chapter 2 Methods 
Virtual screening for multi-target agents by combinatorial machine learning 
methods is usually consisted of the following 4 components: (I) data collection, 
analysis and processing from pharmaceutical datasets and chemical compound 
libraries of known single and multi-target agents (section 2.1), (II) 
physicochemical and structural descriptions of the compounds in the dataset 
(section 2.2) and (III) a statistical learning method (section 2.3 and 2.4) to 
analyze the pharmaceutical datasets (component (I)) in the form of descriptors 
(component (II)), and (IV)the evaluation of the virtual screening models. This 
chapter describes in details the four components and elaborates all the methods 
used in this work for developing combinatorial virtual screening tools and their 
evaluation measurements. 
 
2.1 Data Collection and Processing 
Sufficient, good quality data are critical for drug discovery and especially 
essential for in-silico approaches which rely on the quantity and quality of the 
available data.  Enormous amount of data about small molecules and their related 
information have been accumulated in various scientific literatures and databases. 
Table 2-1 lists some of the important small molecule databases. 
 
The datasets used in this work mainly come from the following two types of 
sources. We collected data from credible journals such as Bioorganic & Medicinal 





Chemistry Letters, Bioorganic & Medicinal Chemistry, European Journal of 
Medicinal Chemistry, European Journal of Organic Chemistry and Journal of 
Medicinal Chemistry, etc. Additionally, I use databases that contain accurate and 
reliable data such as PubChem and ChEMBL (96). 
 







PubChem  http://nihroadmap.nih.gov 
ZINC  http://zinc.docking.org/  
ChEMBL http://www.ebi.ac.uk/chembl/  
DrugBank  http://www.drugbank.ca/  
eMolecules  http://www.emolecules.com/  
WOMBAT http://www.sunsetmolecular.com 
  





 2.1.1 Analysis of data quality and diversity 
The reliability of in-silico approaches of pharmacological properties classification 
depends on the availability of high quality pharmacological data with low 
experimental errors (97). Ideally, the measurements of pharmacological data 
properties should be conducted with a same protocol so that there is a common 
ground to compare different compounds with each other. However, some 
pharmacological properties measurements have been used only for a limited 
number of compounds and most pharmacological properties measurements are 
rarely determined by the same protocol. Thus the collected data consist of 
compound data measured by different protocols and the incorporation of 
additional experimental information. To maintain the stability of data quality, in 
this work, several methods are adopted to ensure that inter-laboratory variations 
caused by different experimental protocols do not significantly affect the quality 
of the training sets. The pharmacological property measurements for data were 
investigated and the ones that contain large variations in experimental protocols 
compared to the majority of the data are filtered out. It is estimated that the most 
common range of the pharmacological properties measurements for the 
compounds investigated in more than one source was used to select compounds 
for the different classes (98).  
 
Diversity Index (DI) is employed to evaluate the structural diversity of a 
collection of compounds. It is defined as the average value of the similarity 
between pairs of compounds in a dataset (99), 
















    (1) 
where ),( jisim  is a measure of similarity between compounds i  and j , D is the 
dataset and |D| is set cardinality (number of elements of the set). The dataset is 
more diverse when DI approaches 0. Tanimoto coefficient (34) was used to 
compute ),( jisim  in this study, 
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where k  is the number of molecular descriptors calculated for the compounds in 
the datasets.  The concept of molecular descriptors will be introduced in chapter 
2.2. 
  





2.1.2 Redundancy within the datasets 
In this study, the data were collected from varied sources. This approach can 
enrich the diversity in the datasets and reduce the potential bias that may arise 
from a monotonic due to the preferences of the researchers. However, since the 
data are presented by independent researchers who don’t share pre-existing 
agreement on their individual data collection. It is likely that there is a certain 
level of redundancy between the datasets from different sources. The redundancy 
could contrarily deduce diversity in the datasets. Therefore, compounds are 
checked for redundancy by comparing exact match of chemical descriptors. In 
this work, scripts are written in Perl to find exact match of chemical descriptors to 
remove redundancy from dataset. 
 
  





2.2 Molecular descriptors  
Molecular descriptors are generated by a logic and mathematical procedure which 
transforms chemical information encoded within a symbolic representation of a 
molecule into a useful number or the result of some standardized experiment. 
They quantitatively represent structural and physicochemical features of 
molecules, and have been extensively used in deriving structure-activity 
relationships (100), quantitative structure activity relationships (101) and VS tools 
(102, 103) (104) including the multi-target VS tools (105). They represent 
compounds in the form of mathematical vectors. This transformation enables the 
statistical analysis of chemical compounds.  
 
2.2.1 Definition and calculation of molecular descriptors 
A number of programs e.g. PaDEL-descriptor (106), DRAGON (107), Molconn-
Z (108), MODEL (109), Chemistry Development Kit (CDK) (110, 111), JOELib 
(112) and Xue descriptor set (113), are available to calculate chemical descriptors. 
These methods can be applied to derive >3,000 molecular descriptors. These 
descriptors include constitutional descriptors, topological descriptors, RDF 
descriptors (114), molecular walk counts (115), 3D-MoRSE descriptors (116), 
BCUT descriptors (117), WHIM descriptors (118), Galvez topological charge 
indices and charge descriptors (119), GETAWAY descriptors (120), 2D 
autocorrelations, functional groups, atom-centred descriptors, aromaticity indices 
(121), Randic molecular profiles (122), electrotopological state descriptors (123), 





linear solvation energy relationship descriptors (124), and other empirical and 
molecular properties. However, not all of the available descriptors are needed to 
fully represent the features of a particular class of compounds. Contrarily, without 
appropriate descriptors, the performance of a developed ML VS tool may be 
affected to some degrees. This is caused by the noise arising from the high 
redundancy and overlapping of the available descriptors. In this work, the Xue 
descriptor set and 98 1D and 2D descriptors were used. These 98 descriptors were 
selected from the descriptors derived from MODEL program by discarding those 
that were redundant and unrelated to the problem studied here. The Xue 
descriptor set and these 98 descriptors are listed in Table 2-2 and Table 2-3. 
Table 2-2 Xue descriptor set 
 






18  Molecular weight, Number of rings, rotatable bonds, H-
bond donors, and H-bond acceptors, Element counts 
Molecular connectivity 
and shape  
28  Molecular connectivity indices, Valence molecular 
connectivity indices, Molecular shape Kappa indices, 
Kappa alpha indices, flexibility index 
Electro-topological 
state  
97  Electrotopological state indices, and Atom type 
electrotopological state indices, Weiner Index, Centric 
Index, Altenburg Index, Balaban Index, Harary Number, 
Schultz Index, PetitJohn R2 Index, PetitJohn D2 Index, 
Mean Distance Index, PetitJohn I2 Index, Information 
Weiner, Balaban RMSD Index, Graph Distance Index  







31  Polarizability index, Hydrogen bond acceptor basicity 
(covalent HBAB), Hydrogen bond donor acidity (covalent 
HBDA), Molecular dipole moment, Absolute hardness, 
Softness, Ionization potential, Electron affinity, Chemical 
potential, Electronegativity index, Electrophilicity index, 
Most positive charge on H, C, N, O atoms, Most negative 
charge on H, C, N, O atoms, Most positive and negative 
charge in a molecule, Sum of squares of charges on 
H,C,N,O and all atoms, Mean of positive charges, Mean of 
negative charges, Mean absolute charge, Relative positive 
charge, Relative negative charge  
Geometrical properties 25 Length vectors (longest distance, longest third atom, 4th 
atom), Molecular van der Waals volume, Solvent 
accessible surface area, Molecular surface area, van der 
Waals surface area, Polar molecular surface area, Sum of 
solvent accessible surface areas of positively charged 
atoms, Sum of solvent accessible surface areas of 
negatively charged atoms, Sum of charge weighted solvent 
accessible surface areas of positively charged atoms, Sum 
of charge weighted solvent accessible surface areas of 
negatively charged atoms, Sum of van der Waals surface 
areas of positively charged atoms, Sum of van der Waals 
surface areas of negatively charged atoms, Sum of charge 
weighted van der Waals surface areas of positively 
charged atoms, Sum of charge weighted van der Waals 
surface areas of negatively charged atoms, Molecular 
rugosity, Molecular globularity, Hydrophilic region, 
Hydrophobic region, Capacity factor, Hydrophilic-
Hydrophobic balance, Hydrophilic Entry Moment, 























18 Number of C,N,O,P,S, Number of total atoms, Number of  rings, Number 
of bonds, Number of non-H bonds, Molecular weight,, Number of 
rotatable bonds, number of H-bond donors, number of H-bond acceptors, 
Number of 5-member aromatic rings, Number of 6-member aromatic 
rings, Number of N heterocyclic rings, Number of O heterocyclic rings, 
Number of S heterocyclic rings. 
Chemical 
properties 




35 Schultz molecular topological index, Gutman molecular topological 
index, Wiener index, Harary index, Gravitational topological index, 
Molecular path count of length 1-6, Total path count, Balaban Index J, 0-
2th valence connectivity index, 0-2th order delta chi index, Pogliani 
index, 0-2th Solvation connectivity index, 1-3th order Kier shape index, 
1-3th order Kappa alpha shape index, Kier Molecular Flexibility Index, 
Topological radius, Graph-theoretical shape coefficient, Eccentricity, 
Centralization, Logp from connectivity. 
Electro-
topological state 
42 Sum of E-state of atom type sCH3, dCH2, ssCH2, dsCH, aaCH, sssCH, 
dssC, aasC, aaaC, sssC, sNH3, sNH2, ssNH2, dNH, ssNH, aaNH, dsN, 
aaN, sssN, ddsN, aOH, sOH, ssO, sSH; Sum of E-state of all heavy atoms, 
all C atoms, all hetero atoms, Sum of E-state of H-bond acceptors, Sum of 
H E-state of atom type HsOH, HdNH, HsSH, HsNH2, HssNH, HaaNH, 
HtCH, HdCH2, HdsCH, HaaCH, HCsats, HCsatu, Havin, Sum of H E-




In my work, the 2D structure of each of the compounds was generated by using 
ChemDraw or downloaded from databases such as  PubChem and BindingDB 
(125). Then they were subsequently converted into 3D structure by using 
CORINA (126). The 3D structure of each compound was manually inspected to 





ensure the proper chirality of each chiral agent. All salts and elements, such as 
sodium or calcium, were removed prior to descriptor calculation. The 
optimization of generated geometries was conducted without symmetry 
restrictions.  The 3D structures of the compounds then were used to compute the 




2.2.2 Scaling of molecular descriptors 
The scaling of molecular descriptors is normally required before they can be used 
in machine learning method. The scaling process of molecular  descriptors 
ensures the unbiased contribution of each descriptor in constructing the prediction 
models (127). There are various types of scaling methods e.g. auto-scaling, range 
scaling, Pareto scaling (128), and feature weighting (127). In this work, range 
scaling is applied to scale the molecular descriptors. Range scaling is conducted 
by dividing the difference between the descriptor value and the minimum value of 

















2.3 Introduction to Machine Learning Methods 
A machine learning (ML) method takes a training set of objects that have 
previously been classified into two or more classes as input. In the 
pharmainformatics context, it is a set of molecules that had previously been tested 
and shown to be either active or inactive. The training samples are represented by 
vectors which can be  binary, categorical or continuous and then they are analyzed 
to develop a decision rule that can be used to classify new  molecules  (the  test 
set)  into  one  of  the  two  classes (129). Machine learning can be divided into 
supervised and unsupervised categories. Supervised machine learning labels the 
training data as a predefined class (130). Example of supervised machine learning 
includes Support Vector Machine, Artificial Neural Network, Decision tree 
learning, Inductive logic programming, Boosting, Gaussian process regression 
etc. Unsupervised machine learning methods use unlabeled training data and the 
learning task involves finding the organization of data (131). Clustering, Adaptive 
Resonance Theory, and Self Organized Map are some of the commonly applied 
unsupervised machine learning methods. In this work, I used SVM, Probabilistic 
Neural Network (PNN) and k nearest neighbor (k-NN). The theories behind these 
methods are described below in subsequent sections. For a comparative study, 










2.3.1 Support vector machine (SVM) method  
Support vector machine (SVM) is designed on the basis of the structural risk 
minimization principle of statistical learning theory (132, 133). It consistently 
shows outstanding classification performance and is less penalized by sample 
redundancy. SVM also has lower risk for over-fitting problem (134, 135). 
 
In linearly separable cases, SVM constructs a hyper-plane to separate active and 
inactive classes of compounds with a maximum margin. A compound is 
represented by a vector xi composed of its molecular descriptors. The hyper-plane 
is constructed by finding another vector w and a parameter b that minimizes 2w  
and satisfies the following conditions: 
 
1, for 1iiby⋅+≥+=+wx
 Class 1 (active)   (1) 
 
1, for 1iiby⋅+≤−=−wx
 Class 2 (inactive)   (2) 
where yi is the class index, w is a vector normal to the hyperplane, /b w  is the 
perpendicular distance from the hyperplane to the origin and 2w  is the 
Euclidean norm of w. Based on w and b, a given vector x can be classified by f(x) 
=
[()]signb⋅+wx
. A positive or negative f(x) value indicates that the vector x 
belongs to the active or inactive class respectively. Linear SVM can then be 
applied to this feature space based on the following decision function: 
0
1
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by maximizing the following Lagrangian expression: 
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0α . A positive or negative f(x) value indicates that the vector x belongs 
to the active or inactive class respectively. However, in classifying compounds of 
diverse structures, nonlinearly separable situation is frequently found to occur (59, 
60, 62, 136-139). In this case, SVM maps the input vectors into a higher 
dimensional feature space by using a kernel function K(xi, xj). We used RBF 
kernel  
2 2/ 2( , ) j ii jK e σ− −= x xx x
   
where σ is the kernel parameter. RBF kernel has 
been extensively used and consistently shown better performance than other 
kernel functions (35, 140, 141).  For a given training set of instance-label pairs (xi, 
yi), i=1, …,l where xi ∈Rn and yi ∈ { 1, − 1 }inl , in SVM, the task of finding the 
hyper-plane which is able to separate active and inactive classes with a maximum 















C>0 is the penalty parameter of the error term. The process of training and using a 
SVM VS model for screening compounds based on their molecular descriptors is 
schematically illustrated in Figure 2-1. 






Figure 2-1 Schematic diagram illustrating the process of the training a prediction 
model and using it for predicting active compounds of a compound class from 
their structurally-derived properties (molecular descriptors) by using support 
vector machines; A, B, E, F and (hj, pj, vj,…) represents such structural and 
physicochemical properties as hydrophobicity, volume, polarizability, etc. 
 





2.3.2 K-nearest neighbor method (k-NN) 
k-NN measures the Euclidean distance 2iD = −x x  between a compound x 
and each individual compound xi in the training set(142, 143). A total of k number 
of vectors nearest to the vector x are used to determine the decision function f(x): 
1






← ∑x x                                                        (6) 
where ( , ) 1 if  and ( , ) 0 if a b a b a b a bδ δ= = = ≠  , arg max refers to the maximum 
value of the function, V is a finite set of vectors {v1,...,vs}  and ˆ ( )f x  is an 
estimate of f(x). Here estimate refers to the class of the majority compound group 
(i.e. inhibitors or non-inhibitors) of the k nearest neighbors. The procedure of k-
NN is illustrated in Figure 2-2. 






Figure 2-2 Schematic diagram illustrating the process of the prediction of 
compounds of a particular property from their structure by using a machine 
learning method – k-nearest neighbors (k-NN). A, B: feature vectors of agents 
with the property; E, F: feature vectors of agents without the property; feature 
vector (hj, pj, vj,…) represents such structural and physicochemical properties as 
hydrophobicity, volume, polarizability, etc. 
 





2.3.3 Probabilistic neural network method 
Probabilistic Neural Network (PNN) belongs to the neural network methods. It is 
designed for classification through the use of Bayes’ optimal decision rule (98):
( ) ( )i i i j j jh c f h c f>x x , where hi and hj are the prior probabilities, ci and cj are the 
costs of misclassification and fi(x) and fj(x) are the probability density function for 
class i and j respectively. An unclassified vector x is classified into population i if 
the product of all the three terms is greater for class i than for any other class j 
(not equal to i). In most applications, the prior probabilities and costs of 
misclassifications are treated as being equal. The probability density function for 
each class for a univariate case can be estimated by using the Parzen’s 
nonparametric estimator(144), 
           
1











                 (7)  
where n is the sample size, σ is a scaling parameter which defines the width of the 
bell curve that surrounds each sample point, W(d) is a weight function which has 
its largest value at d = 0 and (x – xi) is the distance between the unknown vector 
and a vector in the training set. The Parzen’s nonparametric estimator was later 
expanded by Cacoullos for the multivariate case. 
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The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen’s 
estimator. Thus the probability density function for the multivariate case becomes 





           
2
1 1










= −   
 
∑ ∑x                (9)  
The network architectures of PNN are determined by the number of compounds 
and descriptors in the training set. PNN are constituted of four layers, the input 
layer, the pattern layer, the summation layer and the output layer. The input layer 
provides input values to all neurons in the pattern layer and has as many neurons 
as the number of descriptors in the training set. The number of pattern neurons is 
determined by the total number of compounds in the training set. Each pattern 
neuron computes a distance measure between the input and the training case 
represented by that neuron and then subjects the distance measure to the Parzen’s 
nonparametric estimator. The summation layer has a neuron for each class and the 
neurons sum all the pattern neurons’ output corresponding to members of that 
summation neuron’s class to obtain the estimated probability density function for 
that class. Finally, the single neuron in the output layer then estimates the class of 
the unknown vector x by comparing all the probability density function from the 
summation neurons and choosing the class with the highest probability density 
function.  Figure 2-3 illustrates the procedure of PNN method. 
 






Figure 2-3 Schematic diagram illustrating the process of the prediction of the 
prediction of compounds of a particular property from their structure by using a 
machine learning method –probabilistic neural networks (PNN). A, B: feature 
vectors of agents with the property; E, F: feature vectors of agents without the 





property; feature vector (hj, pj, vj,…) represents such structural and 
physicochemical properties as hydrophobicity, volume, polarizability, etc. 
 
 
2.3.4 Tanimoto similarity searching method  
Determining if two compounds are similar to each other or not in a training 
dataset can be conducted by using the Tanimoto coefficient sim(i,j) (34) 
                            (10)
 
where l is the number of molecular descriptors. A compound i is considered to be 
similar to a known active j in the active dataset if the corresponding sim(i,j) value 
is greater than a cut-off value. In this work, in computing sim(i,j), the molecular 
descriptor vectors xis were scaled with respect to all of the MDDR. The cut-off 
values for similarity compounds are typically in the range of 0.8 to 0.9 (145, 146). 
A stricter cut-off value of 0.9 was used in this work. 
 
2.3.5 Generation of putative inactive compounds  
The construction of machine learning prediction models requires both positive 
data (e.g. active compounds) and negative data (e.g. inactive compounds). Apart 
from the use of known inactive compounds and active compounds of other 
biological target classes as putative inactive compounds (47, 58-60, 62-64, 136), a 


























classification of various classes of proteins (147-149) is considered to be used for 
generating putative inactive compounds. An advantage of this approach lies in its 
independence on the knowledge of known inactive compounds and active 
compounds of other biological target classes, which can expend the coverage of 
the “inactive” chemical space when only limited knowledge of inactive 
compounds and compounds of other biological classes can be found. A drawback 
of this approach is the possible inclusion of some undiscovered active compounds 
in the “inactive” class, which may affect the capability of ML methods for 
identifying novel active compounds. Such an adverse effect is expected to be 
relatively small for many biological target classes as explained below. 
 
In applying this approach to proteins, all known proteins are clustered into ~8,900 
protein families based on the clustering of their amino acid sequences (112), and a 
set of putative inactive proteins can be tentatively extracted from a few 
representative proteins in those families without a single known active protein. 
Undiscovered active proteins of a specific functional class typically cover no 
more than a few hundred families, which gives a maximum possible “wrong” 
family representation rate of <10% even when all of the undiscovered active 
proteins are misplaced into the inactive class (150). Importantly, the inclusion of 
the representative of a “wrong” family into the inactive class does not preclude 
other active family members from being classified as active. Statistically, a 
substantial percentage of active members can be classified by ML methods as 
active even if its family representative is in the inactive class (150). Therefore, in 





principle, a reasonably good ML model can be derived from these putative 
inactive samples, which has been confirmed by a number of studies (147-150). 
 
In a similar manner, known compounds can be grouped into compound families 
by clustering them in the chemical space defined by their molecular descriptors 
(40, 151). As ML methods predict compound activities based on their molecular 
descriptors, it is reasonable to represent compounds in terms of molecular 
descriptors and cluster them in the similar manner. We applied K-means 
classification method (40, 151) and used molecular descriptors computed from 
our own software to represent the compounds (152). Then 7,990 cluster families 
were generated from the available compounds in PubChem database, which is 
consistent with the 12,800 compound-occupying neurons (regions of 
topologically close structures) for 26.4 million compounds of up to 11 atoms (8), 
and the 2,851 clusters for 171,045 natural products (153). Analogue groups such 
as steroids and catecholamines are distributed in a few families. Active 
compounds in extensively studied target classes such as those of HIV-1 protease 
inhibitors, DHFR inhibitors, and dopamine antagonists are distributed in 770, 135, 
and 799 families respectively.  The number of undiscovered “active” families in 
PubChem database is expected to be relatively small after then extensive effort in 
searching the known compound libraries for identifying active compounds in 
these target classes, most likely no more than several hundred families. The ratio 
of the undiscovered “active” families (hundreds on less) and the families that 
contain no known active compound (6,000~7,000 based on current version of 





PubChem) for these and possibly many other target classes is expected to be 
<15%. Therefore, it is reasonable to generate putative inactive compounds by 
extracting a few representative compounds of those families that contain no 
known active compound, with a maximum possible “wrong” family 
representation rate of <15% even when all of the undiscovered active compounds 
are misplaced into the inactive class.  
 
CNS active agents are distributed in numerous biological target classes such as 
agonists, antagonists, regulators of G-protein coupled receptors and nuclear 
receptors, blockers and regulators of ion channels, substrates, inhibitors, 
activators, and regulators of transporters, and inhibitors and regulators of enzymes 
involved in the synthesis and metabolism of signaling molecules in the CNS 
system (154). Therefore, agents in this multi-target class are expected to cover a 
significantly larger portion of the chemical space than those of a single target 
class, leading to a possibly higher “wrong” family representation rate because of 
the possibility of higher number of undiscovered active families in the limited 
chemical space covered by the currently available compounds in existing 
databases. As a result, the quality of the putative non-CNS active compounds 
generated by the new approach may be affected to some extent. The new 
approach is expected to become more and more useful for multi-target classes 
when the coverage of chemical space can be significantly expanded as a result of 
increasing volume of the chemical databases. 
 





There are 7,220, 7,855, 7,191, 3,440 families that contain no known HIV-1 
protease inhibitor, DHFR inhibitor, dopamine antagonist, and CNS active agent 
respectively. Thus datasets of 41,254 putative non- HIV-1 protease inhibitors, 
44,856 putative non-DHFR inhibitors, 42,804 putative non-dopamine antagonists, 
and 20,465 putative non-CAN active compounds were generated by random 
selection of 5~6 representative compounds from each of these families 
respectively.  
 
2.4 Virtual Screening Model Validation and Performance 
Measurements 
 
2.4.1 Model validation 
In-silico modeling offers the prediction of the pharmacological properties of 
compounds which have not been clinically or biologically tested. Therefore it is 
important to estimate and validate the predicting ability of the pharmacological-
data-derived models by their performances with the compounds that are not 
present in the training set. In this work, I used 5-fold cross-validation and 
independent validation datasets for this purpose. In 5-fold cross-validation, 
compounds are randomly divided into five subsets of approximately equal size. 
Four subsets are used as the training set for developing a model; the remaining 
one is used as a testing set for evaluating the prediction performance of the model. 
This procedure is repeated five times such that every subset is used as a testing set 





once. The average accuracy of the five time models is seen as the accuracy 
predicting capability of the model constructed with the machine learning method. 
5-fold cross-validation can reflect the average performance of a model, however, 
it has the tendency of underestimating the prediction capability of a classification 
model, especially if important molecular features happen to be contained only in a 
minority of the compounds in the training set (155, 156). Hence if a model has 
relatively low cross-validation accuracy, it can still be predictive (155). Therefore, 
cross-validation alone is not decisive to the performance of a model. To 
complement cross-validation, independent validation datasets are used. They may 
provide a more reliable estimation of the prediction capability of a 
pharmacological property prediction model (157, 158). The independent 
validation dataset should be strictly independent from the training.  
 
2.4.2 Performance evaluation  
Measurements such as sensitivity, specificity and the overall prediction accuracy 
are employed to quantitatively assess the performance of virtual screening 
models. They are defined in terms of true positives TP (pharmaceutical agents 
possessing a specific pharmacological property), true negatives TN 
(pharmaceutical agents not possessing a specific pharmacological property), false 
positives FP (pharmaceutical agents not possessing a specific pharmacological 
property but predicted as agents possessing the specific pharmacological property) 
and false negatives FN (pharmaceutical agents possessing a specific 
pharmacological property but predicted as agents not possessing the specific 





pharmacological property). Sensitivity and specificity are the measurement of 
prediction accuracy for pharmaceutical agents possessing a specific 
pharmacological property and agents not possessing that pharmacological 
property respectively. The overall prediction accuracy (Q) and Matthews 
correlation coefficient (MCC) (159) are used to measure the overall prediction 








                                                                                  (12) 
                                                                    (13) 
                            (14) 
The typical measurements of a model performance in screening large libraries 
include (44) yield (percentage of known positives predicted as virtual hits), hit-
rate (percentage of virtual hits that are known positives), false hit-rate (percentage 
of virtual hits that are known negatives) and enrichment factor EF (magnitude of 
hit-rate improvement over random selection):  
 
Yield = SE                                                                                                  (15) 
Hit-rate = TP/(TP+FP)                                                                              (16) 
False hit-rate = FP/(TP+FP)                                                                     (17) 

















2.4.3 Overfitting problem and its detection 
Overfitting is a major concern in machine learning classification methods. It 
happens when a model that agrees well with the observed data but has no 
predictive ability, which means it does not have any value to unseen or future data. 
There are two main types of overfitting situations: (1) a model more flexible than 
it needs to be and (2) a model including irrelevant descriptors (156). An over-
fitted classification system tends to obtain much higher prediction accuracies in 
the cross-validation sets than in the independent validation sets. Hence frequently 
used method for checking whether a model is overfitted is to compare the 
prediction accuracies in the cross-validation procedure with those found in testing 
independent validation sets (156).  
 
2.5 Combinatorial Machine Learning Methods 
Combinatorial machine learning methods are designed for the discovery of multi-
target agents. They are composed of the machine learning methods applied for 
individual target agents. Virtual hits simultaneously selected by all individual VS 
tools are considered as multi-target virtual hits (160). The multi-target agents 
search capability  of combinatorial machine learning methods is rigorously tested 
by excluding all known multi-target inhibitors from the training datasets and only 
those compounds known to be active against only one target in the target pair 
(these are tentatively referred to as individual-target inhibitors regardless of their 
possible activity against other targets outside the target pair) are used; The 





purpose of this exclusiveness is to test to what extent these individual-target based 
VS tools can identify multi-target inhibitors without explicit knowledge of known 
multi-target inhibitors (105). Target selectivity of combinatorial machine learning 
methods is assessed by using the known individual-target inhibitors of each target 
pair and those in the other target pairs used for the same disease treatment. This 
can reflect the selectivity of combinatorial machine learning methods against 
random selection. Figure 2-4 shows the procedure of combinatorial machine 





















Figure 2-4 The illustration of the procedure for combinatorial machine learning 
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Chapter 3 Pharmainformatics Database Construction 
and Update 
With the exponential increase in pharmaceutical information, it is becoming 
increasingly necessary and important to collect and curate the information to 
provide informative databases to greatly assist the studies of disease mechanisms 
and the discovery of new drugs. Pharmainformatics databases can provide up-to-
date information and data that relate to disease mechanism studies, 
pharmaceutical research and drug development. 
 
3.1 The update of Kinetic Database of Bio-molecular Interaction 
 
3.1.1 Introduction to bio-molecular interactions  
 
Via individual and network actions, bio-molecular interactions participate 
fundamentally in biological, disease, and therapeutic processes (161-164). Over 
the past 20 years, the understanding of the characteristics, organization, evolution 
and complexity of bio-molecular interaction networks in biological systems have 
significantly advanced thanks to the extensive experimental and computational 
studies  (165-168) which also enabled the generation of  genome-scale protein-
protein interactions and the development prediction tools  (166, 167, 169-172) . 
Quite a number of databases have been developed for providing information 
about bio-molecular interactions (e.g. MIPS(173), DIP (174),  BIND  (175) , 
Biocyc (176), MINT (177), Biomodels (178), STRING (179), and IntAct (180)), 





and biological networks and pathways (KEGG (181), BioGRID (182), 
NetworKIN (183), STITCH (184), DOMINE (185), CellCircuits (186), Reactome 
(187) and enzyme reactions (188)).  
3.1.2 New features of updated KDBI 
The updated KDBI includes a 2.3 fold increase of experimental kinetic data and 
four new features. The first new feature enables the access of KDBI entries via 
the list of nucleic acid and pathway names. The second new feature is added for 
facilitating the applications, assessments, and further development of the pathway 
models, it includes the literature-reported kinetic parameter sets of 63 pathway 
simulation models (189-198). The third new feature enables the facility for 
collectively accessing the available kinetic data of multi-step processes (e.g. 
metabolism, pathway segments) collected in KDBI. The fourth new feature 
provides the user with the SBML (199) files for all records of the kinetic 
parameter sets of pathway simulation models.  This format can facilitate the use 
of the relevant data in such software tools as Celldesigner (200), Copasi (201), 
cPath (202), PaVESy (203), and SBMLeditor (204). 
 
3.1.2.1 New Feature 1: nucleic acid and pathway names as KDBI 
entries  
The additional sets of the experimentally determined kinetic data of bio-molecular 
interactions were collected from published literatures.  The updated KDBI now 
contains 2635 protein-protein, 1711 protein-nucleic acid, 11873 protein-small 





molecule, and 1995 nucleic acid-small molecule interactions. Each entry provides 
detailed description about binding or reaction event, participating molecules, 
binding or reaction equation, kinetic data, and related references. Compared to the 
last version of KDBI, the number of entries in the updated KDBI is increased by 
2.3 fold to 19263. As shown in Figure 3-1, kinetic data for protein-protein, small 
molecule-nucleic acid and protein-small molecule interactions is provided in 
terms of one or a combination of kinetic quantities as given in the literature of a 
particular event. These quantities include association/dissociation rate constant, 
on/off rate constant, first/second/third/… order rate constant, catalytic rate 
constant, equilibrium association/dissociation constant, inhibition constant, and 
binding affinity constant, IC50, etc. and experimental conditions (pH value and 
temperature).  
 
Figure 3-1: Experimental kinetic data page showing protein–protein interaction; It includes 
kinetic data and reaction equation (while available) as well as the name of participating molecules 
and description of event. 





3.1.2.2 New Feature 2: pathway simulation models 
Mathematical simulation models of various pathways have been developed and 
extensively used for studying and quantitative understanding of signaling 
dynamics (189-193), signal specific sensing (194) and discrimination (198), 
feedback regulations and crosstalk  (196, 197), and receptor cross-activation  
(195)  and internalization (196). They have greatly assisted the understanding and 
quantitative analysis of complex biological processes and network responses. In 
the mathematical models, the temporal dynamic behaviors of molecular species in 
the pathway are typically described by ordinary differential equations (ODEs). 
The kinetic rate constants of protein–protein, protein-small molecule, protein-
nucleic acid, and other interactions (e.g. binding association rate Kf, binding 
dissociation rate Kb, reaction rate K, reaction turnover rate Kcat, Michaelis–
Menten constant Km) are needed to establish these ODEs. Those data have been 
primarily generated by combinations of experimental data, computed theoretical 
values, and empirically fitted values computational (193-198) . Therefore, in 
order to facilitate further applications, developments, and assessments of the 
published pathway models, in the KDBI update, I collected parameter sets of 63 
published ODE-based models, which can be accessed from the pathway list in the 
“Pathway Simulation Parameters” field in KDBI webpage. Additionally, the data 
type of kinetic data was included to every entry to clearly distinguish its original 
source (experimental or simulation model). In particular, when the data come 
from a simulation model, the cross reference to the original source is provided. 
Figure 3-2 demonstrates a pathway simulation model page. 






Figure 3-2 This page provides kinetic data and reaction equation (when available) as 
well as the name of participating molecules and description of event in the pathway 
simulation models. 
 
3.1.2.3 New Feature 3: multi-step processes of kinetic data  
Multi-step processes have caught the interest and attention and there have been 
published studies providing information about the experimental kinetic data for 
the multiple components involved in multi-step processes (205-207). Some 
examples of these processes include RNA binding activity to translation initiation 
factors eIF4G, 70-kDa Heat Shock Protein polymerization, control of platelet 
function by cyclic AMP, GroEL interaction with conformational states of horse 





cytochrome c, intermolecular catalysis by hairpin ribozymes, antisense RNA 
interaction with its complimentary RNA, nucleotide binding to actin. To facilitate 
the development of pathway simulation models based on these building blocks, 
direct access to the collection of the kinetic data for each of these processes are 
provided in the KDBI update, which can be accessed via a separate search field 
“Multi-step processes” in KDBI webpage. Figure 3-3 illustrates the multi-step 
process data displaying page. 
 
Figure 3-3 Multi-process kinetic data page provides kinetic data and reaction 
equation (when available) as well as the name of participating molecules and 
description of event 





3.1.2.4 New Feature 3: SBML availability  
Incredibly bio-information is being offered by numerous laboratories and 
research groups across the globe and hundreds of software for bioinformatics and 
chemo-informatics are used to process those data. Therefore, it is critical to adopt 
a unified data format that is compatible across the different software platforms. 
To this end, systems Biology Markup Language (SBML) has been developed as a 
free, open, XML-based format for representing biochemical reaction networks, 
and it is a software-independent language for describing models common to 
computational biology research, including cell signaling pathways, metabolic 
pathways, gene regulation, and others (208). Many pathway simulation and 
analysis software tools have built-in SBML compatibility features to allow the 
input, manipulation, simulation and analysis of different pathway models and 
parameters (199, 208-212). To meet the demand for SBML formatted date, the 
SBML files for the parameter sets of all 63 pathway simulation models included 
in KDBI were also created. These files can be downloaded via the link provided 
on the top of the page that displays the relevant kinetic data. Moreover, the SMBL 
viewer is provided for the convenience of the users, which can be found in the 
home page of KDBI. The SBML formatted data are offered in each query result 
page. See Figure 3-4 
 
Figure 3-4 The boxed part is link to where the SBML format data are offered. This link is presented in 
every query result page. 





3.2 Update of Therapeutic Targets Database 
The studies of therapeutic targets (responsible for drug efficacy) and the targeted 
drugs can greatly facilitate both the discovery, validation of new targets and the 
development and optimization of new drug leads.  Therapeutic Target Database 
(TTD) is developed to provide comprehensive information of the known efficacy 
targets and the corresponding approved, clinical trial and investigative drugs. 
Since its last update in 2010, major improvements and updates have been made to 
TTD. First of all, a significant increase of data content (from 1,894 targets and 
5,028 drugs to 2,025 targets and 17,816 drugs plus 3,681 multi-target agents) has 
been made to the updated version. Besides, target validation information (drug 
potency against target, action against disease model, and the effect of target 
knockout, knockdown or genetic variations) for 932 targets (351 successful, 252 
clincial trial, 34 discontinued and 295 research targets), and 841 quantitative 
structure activity relationship (QSAR) models for active compounds of 228 
targets (71 of the targets are successful target, 20 are clinical trial and 30 are 
research targets) are added to the updates. Additionally, drug combinations and 
nature-derived drugs information are presented in the updated TTD. These 
updates are particularly useful for providing relevant information and facilitating 
target discovery and validation, drug lead discovery and optimization, and the 
development of multi-target drugs.  





3.2.1 Target validation  
The decision to develop a drug against a particular target is usually a considerable 
commitment in terms of time and money. Once a target enters a pharmaceutical 
company's pipeline, it can take about 12 years to develop a marketable drug. Each 
new drug that reaches the market represents research and development costs of 
close to US$1 billion (213). Despite the huge investment in time and money, the 
number of NDAs (New Drug Applications) approved each year by the Food and 
Drug Administration (FDA), however, has declined from 53 in 1996 to 35 in 1999 
to 17 in 2002 to 15 in 2005. 
After passing the pre-clinical trials, pre-drugs will go through clinical trials, 
which are the tests conducted on humans. There are usually three stages in the 
clinical trials: Phase I (screening for safety), Phase II (establishing the testing 
protocol), Phase III (final testing). And sometimes, Phase IV will be conducted 
for post-approval studies. Drugs fail in the clinic usually for two basic reasons: it 
is either that they do not work as they were expected or they prove to be unsafe 
for patients. The ultimately ideal way to be completely certain that a drug can 
affect a protein instrumentally in a given disease is to test the idea in humans. 
Obviously such clinical trials cannot be applied for initial drug development, 
which means that a potential target must undergo other validation processes to 
clearly define its role in disease before drugs are sought that act against it, or 
before it is used to screen large numbers of compounds for drug activity. There 
are several aspects that can reflect a target’s validation. Such measurements 





include the target’s association with disease pathology, its expression in cells 
linked to disease pathology and animal models. A relatively new route to target 
validation adopts the disrupting of gene expression. This is to reduce the amount 
of the corresponding protein, and so to identify the physiological role of the 
target. Examples of this technique include gene knockouts, antisense technology 
and RNA interference. 
To facilitate the validation of current targets, TTD update includes the target 
validation data for 932 targets. The validation information collected is classified 
into three types: drug potency against target, action against disease model, and the 
effect of target knockout, knockdown or genetic variations. Currently, TTD 
provides complete or partial validation information for 932 targets (351 
successful, 252 clinical trial, 34 discontinued and 295 research targets). This 
collection of target validation data can offer a good reference for drug 
development. Figure 3-5 gives an example of the TTD update in target validation. 






Figure 3-5 An example for target validation information presented in the updated 
TTD 
 
3.2.2 QSAR models 
Quantitative structure-activity relationships (QSAR) attempts to correlate 
structural or property descriptors of compounds with their activities. QSAR use 
physicochemical descriptors to represent the features of the compounds for model 





construction. These physicochemical descriptors, which include parameters to 
account for hydrophobicity, topology, electronic properties, and steric effects, are 
determined empirically or, more recently, by computational methods. Activities 
used in QSAR include chemical measurements and biological assays.  QSAR 
methods have been intensively applied in biomolecular discovery and drug design 
(214).  A great number of QSAR models have been constructed for various targets 
with descriptors of all kinds. Therefore, it would be very helpful to summarize as 
many as possible already constructed models to provide an informative and 
convenient reference. TTD now includes 841 QSAR models for active 
compounds of 228 distinct chemical types against 121 targets (71 of the targets 
are successful target, 20 are clinical trial and 30 are research targets). It provides 
two means for search: search by drug target name and search by chemical type. 
And in the search result page, QSAR models are described in details in the pdf 
format files which can be downloaded in the result page by clicking “QSAR 
model page”. Figure 3-6 shows the search page for the QSAR update of TTD and 


















Figure 3-7 An example of the search page for QSAR models. Detailed 









3.2.3 Other update features 
 
Multi-target agents have become a new trend in drug design as this approach is 
showing the hope to conquer the issues confronting the traditional single-target 
drugs such as low efficacy and side effects  (215). There have been intensive 
studies with rigorous analysis on the effect of drug combinations for which the 
combination effect has been evaluated by and for which relevant molecular 
interaction profiles of the drugs involved. These combinations are found to reveal 
general and specific modes of action (88). Nature derived drugs have always been 
widely applied by the traditional medicines of many cultures. Recently, Low drug 
productivity has renewed interest in natural products as drug-discovery sources 
(216). In order to keep pace with these new drug discovery trends, TTD updates 
provides structure and potency information of 3,681 multi target agents against 
108 target pairs, drug-combination data of 72, 14 and 4 pharmacodynamically 
synergistic, additive, and antagonist combinations respectively, 19 and 7 
pharmacokinetically potentiative and reductive combinations together with their 
mode of actions and combination mechanisms and 939, 369 and 119 nature-
derived approved, clinical trial and preclinical drugs together with their species 
origin information. All data are available for user to download. Figure 3-8, 
Figure 3-9 and Figure 3-10 present the downloading page for these data. Right 
click “Click to save” and choose “Save link as” option, the data then can be saved 
to the users’ preferred destination. 





          
                                                     Figure 3-8 
       
                                                 Figure 3-9 
 
      
                                                  Figure 3-10 
Figure 3-8, Figure 3-9, Figure 3-10 Downloading pages for multi-target agents, 
Drug combination information and Nature-derived drugs
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Chapter 4 Preliminary Tests of Combinatorial Machine 
Learning Methods in Screening Multi-target Agents  
4.1 Introduction: Multi-target Kinase Inhibitor Therapeutics for 
Cancer Treatment 
Tyrosine kinases (TKs) are usually classified into receptor tyrosine kinases 
(RTKs) (e.g. epidermal growth factor receptor (EGFR), vascular endothelial 
growth factor (VEGFR)) and cytoplasmic/non-receptor kinase (e.g. Src, Lck). 
They play pivotal roles in diverse cellular activities including growth, 
differentiation, metabolism, adhesion, motility, death (217). For example, EGFR 
is found to be overexpressed or aberrantly activated in the most common solid 
turmors, including non-small cell lung cancer, breast cancer, prostate cancer and 
colon cancer. It has been proven that tyrosine kinases have particularly important 
implications in development of cancers. Therefore, they have emerged as 
clinically useful drug target molecules for treating certain types of cancer (218). 
Several tyrosine kinase inhibitors  (TKIs) (e.g. Gefitinib as EGFR inhibitor, 
Avastin as VEGFR inhibitor) have stumblingly survived the drug development 
stages and been applied for cancer treatment in clinical treatment of cancer (219).  
Despite the discovery and application of those kinase inhibitors, almost inevitably, 
cancer patients treated with single-target develop drug resistance and suffer a 
relapse. Moreover, many tumors are multi-factorial  and  are  linked  to  defects  
in  more  than  one  signaling  pathways,  and  the  inhibition  of  a  single  
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molecule  may  not  be sufficient to interfere efficiently with disease progression 
(220). As a result, a  multi-target  approach  has become a prevailing idea and  the 
new  generation  of TKIs  is  selected  on  the  basis  of  their  ability  
simultaneously  to  target  different  molecules.  Based on their importance in 
cancerogenesis implications, I selected five TKs (EGFR, FGFR, VEGFR, Src and 
Lck) to test virtual screening (VS) for the studies of inhibitors of the four dual-
target pair, EGFR-FGFR, EGFR-Src, VEGFR-Lck and Src-Lck. The strategy is to 
use experimentally obtained small-scale multi-target kinase inhibitors profiles to 
predict  inhibitors in a larger kinase set (221) by means of virtual screening. In 
principle, single-target VS tools may be combined to collectively identify multi-
target agents. This is practically useful when the individual VS tools have 
sufficiently high yields and low false-hit rates. High yields can compensate for the 
reduced collective yields of combinatorial VS tools (For two statistically-
independent VS tools of 50%-70% yields, the collective yield of their 
combination is roughly the product of the yield of individual tools, which is 25%-
49%). Low false-hit rates contribute to  high enrichment factors in searching 
multi-target agents that are more sparsely distributed in the chemical space than 
non-dual inhibitors (Table 4-1). 




Table 4-1 Datasets of dual-inhibitors and non-dual-inhibitors of the kinase-pairs used for developing and testing combinatorial SVM virtual 
screening tools; Additional sets of 13.56 million PubChem compounds and 168 thousand MDDR active compounds were also used for the 
test. 
Kinase Pair  Inhibitors in Training Sets Inhibitors and Other Compounds in Testing Set 
Kinase A – 
Kinase B 





A and B 
 No of 
inhibitors of 
A that are 
non-
inhibitor of 
B (No of 
families) 
No of  
these 
inhibitors 














of A and 




of B that 
are non-
inhibitor of 











No of  
these 
inhibitors 





of A and 





of A and 
B (No of 
families) 









No (%) of 
dual-inhibitors 
of A and B as 
inhibitor of at 
least one of 
the other 5 
kinases 
studied in this 
work 
No (%) of 
dual-
inhibitors 
of A and B 
as inhibitor 
of more 







EGFR-FGFR 1303 (388) 284 (52) 160 (22) 392 (131) 154 (52) 124 (27) 71 (39) 37 (52.1%) 70 (98.6%) 2 (2.8%) 1001 
EGFR-Src 1262 (372) 331 (73) 166 (31) 748 (216) 243 (73) 168 (38) 112 (64) 46 (41.1%) 46 (41.1%) 2 (1.8%) 1127 
VEGFR-Lck 1232 (427) 220 (69) 102 (17) 445 (171) 206 (69) 52 (11) 61 (23) 29 (47.5%) 37 (60.7%) 0 (0.0%) 413 
Src-Lck 804 (236) 222 (49) 98 (11) 450 (175) 160 (49) 23 (9) 56 (17) 23 (41.1%) 38 (67.9%) 0 (0.0%) 276 
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4.2 Materials and Methods 
4.2.1 Compound collection, training and testing datasets, 
molecular descriptors 
We collected a total of 233-1,316 non-dual inhibitors of EGFR, VEGFR, FGFR, 
Src, Lck and 56-188 dual inhibitors of EGFR-FGFR, EGFR-Src, VEGFR-Lck,, 
and Src-Lck, each with IC50≤10µM, were collected from the litterature (222-231) 
and the BindingDB database (125). Here dual-inhibitors and non-dual inhibitors 
of a kinase-pair are defined as inhibitors of both and one of the two kinases 
respectively regardless of their activities against other kinases. Table 4-1 
summarizes the statistics of these inhibitors and MDDR compounds similar to at 
least one dual-inhibitor. The implication of machine learning methods requires 
both positive (e.g. the active compounds) and negative data (e.g. the inactive 
compounds). As few non-inhibitors have been reported, putative non-inhibitors of 
each kinase were generated by using our published method that requires no 
knowledge of inactive compounds or active compounds of other target classes and 
enables more expanded coverage of the “non-inhibitor” chemical space (85, 102). 
First, 13.56 million PubChem and 168 thousand MDDR compounds were 
clustered into 8,993 compound families of similar molecular descriptors (151). 
These are consistent with the reported 12,800 compound-occupying neurons 
(regions of topologically close structures) for 26.4 million compounds of up to 11 
atoms (8), and 2,851 clusters for 171,045 natural products (153). A total of 
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42,670- 44,115 compounds extracted from the 8,534-8,823 families (5 per family) 
that contain no known inhibitor were used as the putative non-inhibitors.  
 
In this study, I used a total of 98 important descriptors calculated by the program 
MODEL. The details about molecular descriptors have been explained in 
Chapter 2 Section 2.2.1 
 
4.2.2 Computational methods  
Support Vector Machine (SVM) is based on the structural risk minimization 
principle of statistical learning theory (132). SVM can detect active compounds 
fast by differentiating physicochemical profiles rather than structural similarity to 
active compounds per se. It does not require knowledge of target structures and 
the computation of structural flexibility, activity-related features, solvation effects 
and binding affinities. It has shown outstanding classification performance, less 
chance being penalized by sample redundancy, low over-fitting risks. It  is 
capable of accommodating large and structurally diverse training and testing 
datasets, and is fast in performing classification tasks (134, 135). Although the 
performance of SVM critically depends on the diversity of training datasets thus 
the limited knowledge of known inhibitors for many kinase targets may hinder the 
application of sufficiently good SVM VS, its high yields and low false-hit rates in 
searching single-target agents (103) sometimes even based on sparsely distributed 
active compounds (102) still make it a potentially good virtual screening tool for 
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the exploration of multi-target agents. In this study, I derived multi-target SVM 
VS tool: combinatorial SVMs (COMBI-SMV), which combines the prediction of 
two separate SVM classifier for each the multiple kinases.  
 
Figure 4-1 illustrates the application of COMBI-SVM for searching multi-target 
inhibitors. The SVM VS models were developed by using a hard margin 
c=100,000 and their σ values are in the range of 0.1-2. In terms of the numbers of 
true positives TP (true inhibitors), true negatives TN (true non-inhibitors), false 
positives FP (false inhibitors), and false negatives FN (false non-inhibitors), the 
yield and false-hit rate are given by TP/(TP+FN) and FP/(TP+FP) respectively. 
 
Figure 4-1 Illustration of combinatorial support vector machines method 
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4.3 Results and Discussion 
4.3.1 Virtual screening performance of Combinatorial SVM in 
searching kinase dual-inhibitors from large libraries 
The performance of combinatorial SVM (COMBI-SVM) for identifying the 4 
dual-kinase inhibitors is summarized in Table 4-2. We used 5-fold cross-
validation to select the COMBI-SVM model parameters for the evaluated kinases 
and they reside in the ranges of σ=0.5~0.8.  The dual-inhibitor yields are 40.9% 
for EGFR-FGFR, 26.8% for EGFR-Src, 52.6% for VEGFR-Lck, and 48.2% for 
Src-Lck respectively.  Besides, the yields for the intra-PTK group are comparable 
to the expected 25%-49% yields of combinations of good VS tools with 
individual yields of 50%-70%. This shows reasonably good capability for 
COMBI-SVM in identifying multi-target agents for kinase-pairs within a protein 
kinase group without requiring explicit knowledge of multi-target agents. 
 
The target selectivity is conducted by two means. Firstly, I tested the target 
selectivity of COMBI-SVM by screening the 233-1,316 non-dual inhibitors of the 
4 kinase pairs. The misidentifying rates are 10.1% and 8.7% of the non-dual 
inhibitors of the kinase pair as dual-inhibitors for EGFR-FGFR, 12.9% and 11.1% 
for EGFR-Src, 6.6% and 29.2% for VEGFR-Lck, 15.8% and 18.7% for Src-Lck 
(see Table 4-2). The misidentification of a substantial percentage of non-dual 
inhibitors as dual-inhibitors might be caused by the following two reasons.  1) 
SVMs were trained exclusively by non-dual inhibitors, which may make it 
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difficult for a SVM model to fully distinguish dual and non-dual inhibitors. 2) 
Some of the misidentified non-dual inhibitors are probably true dual-inhibitors not 
yet experimentally tested for multi-target activities. Hence the “mistaken” 
selection of these non-dual inhibitors can still be utilized in tests as possible dual-
inhibitor candidates. Therefore, COMBI-SVMs have reasonably good selectivity 
in distinguishing dual-inhibitors from non-dual inhibitors.  
 
Virtual-hit rates and false-hit rates of COMBI-SVMs in detecting compounds 
similar in the structural and physicochemical properties to the training datasets 
were measured by using 276-1,127  MDDR compounds similar to a dual-inhibitor 
of each kinase-pair. Similarity was defined by Tanimoto similarity coefficient 
≥0.9 between a MDDR compound and its closest dual-inhibitor (102). COMBI-
SVMs identified 65 virtual hits from 1,001 MDDR compounds (6.5%) for EGFR-
FGFR, 24 from 1,127 MDDR compounds (2.1%) for EGFR-Src, 21 from 413 
MDDR compounds (5.1%) for VEGFR-Lck, and 26 from 276 MDDR compounds 
(9.4%) for Src-Lck. 
 
The virtual-hit rates and thus false hit rates were tested by screening large 
libraries of 168 thousand MDDR and 13.56 million PubChem database. The 
numbers of virtual-hits and virtual-hit rates in screening 168 thousand MDDR 
compounds are 126 and 0.07% for EGFR-FGFR, 162 and 0.096% for EGFR-Src, 
170 and 0.1% for VEGFR-Lck, and 131 and 0.078% for Src-Lck. The numbers of 
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virtual-hits and virtual-hit rates in screening 13.56M PubChem compounds are 
2,200 and 0.015% for EGFR-FGFR, 4,471 and 0.033% for EGFR-Src, 4,817 and 
0.036% for VEGFR-Lck,  2,674 and 0.02% for Src-Lck. COMBI-SVM hence 
showed significantly low false-hit rates in screening large libraries.  
 
Analysis of the MDDR virtual hits showed that substantial percentages of the 
MDDR virtual-hits belong to the classes of antineoplastic, tyrosine-specific 
protein kinase inhibitors, and signal transduction inhibitors (Table 4-3). As some 
of these virtual-hits may be true dual-inhibitors, the actual number of true false-
hits may be smaller than the total number of virtual-hits for each kinase-pair. 
Hence, the false-hit rates of the combinatorial SVMs are at most equal to and 
likely less than the virtual-hit rates. Hence the false-hit rates are ≤2.13%-9.4% in 
screening 276-1,127 MDDR similarity compounds, ≤0.078%-0.10% in screening 
168 thousand MDDR compounds, and ≤0.002%-0.011% in screening 13.56 
million PubChem compounds, which are comparable and in some cases better 
than single-target false-hit rates of 0.0054%-8.3% of single-target SVMs (29, 
102), 0.08%-3% of structure-based methods, 0.1%-5% by other machine learning 









Table 4-2 Virtual screening performance of combinatorial SVMs for identifying dual-inhibitors of 4 combinations of EGFR, 
VEGFR,FGFR, Src and Lck 
 
Kinase  Virtual Screening Performance 
  Dual inhibitors Non-dual inhibitors of the same 
kinase pair 
MDDR compounds 
similar to dual 
inhibitors 







  Yield No (%) of 
identified true 
hits outside the 
common training 
active families of 
both kinases 
False hit rate for 
inhibitors of 
kinase A 
False hit rate for 
inhibitors of 
kinase B 
 Virtual hit rate (No 
of virtual hits) 
Virtual hit rate (No 
of virtual hits) 
Virtual hit rate 
(No of virtual 
hits) 
Virtual hit rate 
(No of virtual 
hits) 
EGFR-FGFR 40.90% 6 (8.5%) 10.10% 8.70% 6.5% (65) 0.07% (126) 0.016% (2200) 0.004% (36) 
EGFR-Src 26.80% 13 (11.6%) 12.90% 11.10% 2.13% (24) 0.096% (162) 0.033% (4471) 0.007% (76) 
VEGFR-Lck 52.60% 8 (13.1%) 6.60% 29.20% 5.1% (21) 0.10% (170) 0.036% (4817) 0.011% (113) 
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Table 4-3 MDDR classes that contain higher percentage (≥9%) of virtual-hits 
identified by combinatorial SVMs in screening 168 thousand MDDR compounds 
for dual-inhibitors of 4 combinations of EGFR, VEGFR, FGFR, Src and Lck 





MDDR Classes that Contain Higher 










EGFR-FGFR 126 Antineoplastic 78 0.40% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
47 4.00% 
Antiarthritic 37 0.30% 
Signal Transduction Inhibitor 23 1.10% 
Antiangiogenic 16 1.00% 
EGFR-Src 162 Antineoplastic 95 0.40% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
42 3.60% 
Signal Transduction Inhibitor 39 1.90% 
Antiangiogenic 21 1.30% 
Antiarthritic 15 0.10% 
VEGFR-Lck 170 Antineoplastic 87 0.40% 
Antiarthritic 42 0.40% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
36 3.00% 
Signal Transduction Inhibitor 31 1.50% 
Antiangiogenic 16 1.00% 
Atherosclerosis Therapy 10 0.90% 
Antiarthritic 10 0.10% 
Src-Lck 131 Antineoplastic 65 0.30% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
34 2.90% 
Antiarthritic 23 0.20% 
Signal Transduction Inhibitor 17 0.80% 
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4.3.2 Analysis of combinatorial sVM identified MDDR virtual hits 
The virtual hits of MDDR detected by combinatorial SVM (COMBI-SVM) were 
analyzed based on the known biological or therapeutic target classes specified in 
MDDR. Table 4-3 has listed the MDDR classes that contain higher percentage 
(≥9%) of COMBI-SVM virtual-hits and the percentage values. It is shown that 
65-95 (41.6%-61.9%) of the 126-170 virtual-hits belong to the antineoplastic 
class, which represent 0.30%-0.40% of the 21,557 MDDR compounds in the 
class. In particular, 34-47 (21.2%-37.3%) of the virtual-hits belong to the 
tyrosine-specific protein kinase inhibitor class, which represents 2.9%-4.00% of 
the 1,181 MDDR compounds in the class. Moreover, 17-39 (13.0%-24.1%) of the 
virtual-hits are the numbers of the signal transduction inhibitor representing 
0.80%-1.9% of the 2,037 members in this class. Therefore, many of the COMBI-
SVM virtual-hits are antineoplastic compounds that may also inhibit tyrosine 
kinases and possibly other kinases involved in signal transduction, angiogenesis 
and other cancer-related pathways. Although some of these kinase inhibitors 
might be true dual-inhibitors of specific kinase pairs, the majority of them are 
expected to be false selection of non-dual inhibitors of the same kinase-pairs (at 
6.6%-29.2% false-hit rates).  
 
Some of the COMBI-SVM virtual hits belong to the antiarthritic class. Four of the 
evaluated kinases have been linked to arthritis in the literature. EGFR-like 
receptor stimulates synovial cells and its elevated activities may be involved in 
the pathogenesis of rheumatoid arthritis (29). VEGF has also been related to such 
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autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, and 
multiple sclerosis (233). FGFR may partly mediates osteoarthritis (234). Lck 
inhibition leads to immunosuppression and has been explored for the treatment of 
rheumatoid arthritis and asthma (235). Therefore, some of the COMBI-SVM 
virtual-hits in the antiarthritic class could actually be capable of producing 
antiarthritic activities.  
 
Moreover, Multiple FGFRs are elevated in atherosclerotic lesions in apoE-/- 
micand and active FGFR-1 signalling promotes atherosclerosis development via 
increased SMC proliferation and by augmenting macrophage accumulation via 
increased expression of MCP-1 and factors promoting macrophage retention in 
lesions (236). Hence, some of the COMBI-SVM virtual hits in the atherosclerosis 
therapy could act as dual inhibitors of the two kinases.
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In these preliminary tests for the search of dual-kinase inhibitors, combinatorial 
SVM (COMBI-SVM) VS tools developed by exclusively using non-dual 
inhibitors showed good yields for dual-inhibitors of several anticancer target 
kinase pairs and in many cases. The capability of the combinatorial SVMs and 
other VS tools in identifying multi-kinase inhibitors and other multi-target agents 
may be further enhanced by incorporating knowledge of multi-target agents into 
VS tool development processes. When more multi-target kinase inhibitors are 
found and tested to prove effective on their targets, it is possible to introduce 
more comprehensive elements of distinguished structural and physicochemical 
features of selective multi-target agents into the training of combinatorial VS 
tools. This could in turn enhance more effective identification of selective multi-
target agents. In order to improve the target selectivity, the multi-target VS tools 
can be combined with structure-based filters. Because of their high computing 
speed and generalization capability, combinatorial SVM can be potentially 
studied and applied as useful VS tools to complement other VS methods or to be 
used as part of integrated VS tools in facilitating the discovery of multi-kinase 
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Chapter 5 The Application of Combinatorial Machine 
Learning Methods in Virtual Screening of Selective 
Multi-target Antidepressant Agents 
5.1 Introduction 
Major depression is a prevailing, heterogeneous, and often incapacitating 
disorder. It is triggered by complex patterns such as genetic, epigenetic, 
developmental, and environmental factors (237). Major depression is 
characterized as an episode of change in mood that lasts for weeks or months. It is 
one of the most severe types of depression. It usually involves a low or irritable 
mood and/or a loss of interest or pleasure in usual activities. It interferes with 
one's normal functioning and often includes physical symptoms. A person may 
experience only one episode of major depressive disorder, but often there are 
repeated episodes over an individual's lifetime. The effects of major depression 
could be devastating and lead to suicide. Hence antidepressants have become one 
of the largest therapeutic areas of current drug market (63). Despite the efforts 
spent in the treatment of major depression, Antidepressant drug discovery has 
been a complex task due to incomplete understanding of neurobiological basis of 
depression. A primary anti-depression strategy is to inhibit monoamine reuptakes, 
such as serotonin reuptake, by both single-target and multi-target drugs (95). 
Commonly used antidepressants, such as the selective serotonin (5-HT) reuptake 
inhibitors (SSRIs) (e.g. Fluoxetine) are often effective, but the full efficacy takes 
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several weeks to achieve and many patients only partially respond to the drugs 
while some others remain refractory (237). Single-target drugs (78, 85) frequently 
encounter reduced efficacy and drug resistance problems caused by network 
robustness (78), redundancy (79), crosstalk (80), compensatory and neutralizing 
actions (81), anti-target and counter-target activities (82), and on-target and off-
target toxicities (83) . Multi-target drugs are particularly useful for avoiding these 
problems.  
 
Multi-target monoamine inhibitor drugs achieve enhanced efficacies by several 
mechanisms. The first one involves the inhibition of multiple monoamine 
reuptakes (1). The simultaneous blockade of complementary monoamine 
reuptakes synergistically enhances the overall therapeutic efficacy (238). Specific 
types of monoamines in CNS are reduced both by a primary monoamine 
transporter and by alternative transporters (239, 240). For instance, 5-HT is 
reduced primarily by serotonin transporter (SERT), and secondarily by 
noradrenaline transporter (NET) and dopamine transporter (DAT) particularly at 
high levels of 5-HT and/or when SERT function/expression is compromised 
(240). Therefore, inhibition of one monoamine reduction route is complemented 
by the inhibition of the other routes to reduce their compensatory activities, 
leading to therapeutic synergy. This multi-target strategy is the basis for 
developing dual serotonin reuptake and noradrenaline reuptake inhibitors  
(NETSRIs) as antidepressant drugs of fast and enhanced therapeutic effects (241). 
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DES-VENLATAFINE and TESOFENSINE are good examples of NETSRI and 
dual SERT and DAT inhibitor respectively (Figure 5-1).  
The second mechanism involves collective monoamine reuptake inhibition and 
receptor antagonism. For instance, it has been reported that increased release of 5-
HT by SERT inhibition stimulates 5-HT1A, 5-HT1B, and 5-HT1C autoreceptors, 
which subsequently reduces 5-HT release, thereby delaying the therapeutic effect 
of serotonin reuptake inhibitors until the 5-HT1A and 5-HT1B/1C autoreceptors 
become desensitized (242). This counteractive effect can be reduced by 
simultaneous targeting of serotonin transporters and 5-HT1A, 5-HT1B or 5-HT1C 
receptors. Indeed, co-administration of a 5-HT1A receptor antagonist with a 
selective serotonin reuptake inhibitor leads to an immediate increase in CNS 5-
HT levels (243) and shortened onset of anxiolytic activity (244). SSA-426 is an 
example of dual SERT and 5-HT1A receptor antagonist (Figure 5-1). Histamine 
H3 receptor also promotes counteractive effect against serotonin reuptake 
inhibition by mediating the inhibition of serotonin release in the brain (245, 246). 
Therefore, in some circumstances, simultaneous targeting of serotonin reuptake 
transporter and histamine H3 receptor achieves an improved antidepressant effect 
by more enhanced 5-HT release (247).  
 
Another mechanism involves bimodal antidepressant actions. This approach aims 
at reducing the undesirable actions of selective serotonin reuptake inhibitors 
(SSRIs) through multi-targeted inhibition of other related receptors. Some of the 
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undesirable actions of SSRIs, such as the short-term anxiety, arise from 
stimulation of 5-HT2C receptor, and 5-HT2C receptors also mediate the inhibitory 
effects of SSRIs on sleep, sexual function, and appetite (1). Therefore, serotonin 
reuptake inhibitors with antagonist activities against 5-HT2C receptor sites are 
expected to show a better tolerability than SSRIs (1). AGOMELATINE is a dual 
serotonin reuptake inhibitor and 5-HT2C receptor antagonist (5HT2cAntags) 
(Figure 1) with clinically proven activity against major depression. The blockade 
of neurokinin 1 (NK1) receptors by NK1 receptor antagonists (NK1Antags) not 
only complement the effects of serotonin reuptake inhibition but also accelerate 
the long-term facilitating influence of SSRIs on serotonergic transmission (237).  
Therefore, dual serotonin reuptake inhibitor and NK1 receptor antagonist, such as 
UCB (Figure 5-1), is expected to be more efficacious and faster in achieving 
therapeutic effects than SSRIs.  Moreover, dual serotonin reuptake inhibitor and 
melanocortin 4 (MC4) receptor antagonist (MC4Antags), such as MCL10004 
(Figure 1), has been found to interlink neuropeptide receptor antagonist activity 
with SRI activity to synergistically improve mood (237).  
 
Extensive efforts have been directed at the development of multi-target serotonin 
reuptake inhibitors (e.g. dual serotonin reuptake and noradrenaline reuptake 
inhibitors (NETSRIs) (248, 249), dual serotonin reuptake inhibitor and 5-HT1A 
receptor antagonists (5HT1aSRIs) (250, 251), dual serotonin reuptake inhibitor 
and 5-HT1B receptor antagonists (5HT1bSRIs) (252), dual serotonin reuptake 
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inhibitor and H3 receptor antagonists (H3SRIs) (247), dual serotonin reuptake 
inhibitor and 5-HT2C receptor antagonists (5HT2cSRIs) (253), dual serotonin 
reuptake inhibitor and MC4 receptor antagonists (MC4SRIs) (254) and dual 
serotonin reuptake inhibitor and NK1 receptor antagonists (NK1SRIs) (255)) 
based on the above mechanisms. While in-silico methods have been extensively 
used for searching selective serotonin reuptake inhibitors (256, 257), 
noradrenaline reuptake inhibitors (258),(259), 5HT1A receptor antagonists (260, 
261) and H3 receptor antagonists (262, 263), these methods have been used in a 
few published works for searching NETSRIs, 5HT1aSRIs, 5HT1bSRIs, H3SRIs, 
5HT2cSRIs, MC4SRIs and NK1SRIs (252) (264, 265). Therefore, in order to 
identify multi-target agents that are more sparsely distributed in the chemical 
space than single-target agents, there is a strong need to explore in-silico methods 
more extensively, particularly those methods capable of searching large 
compound libraries at good yields and low false-hit rates.  
 
In this work, I used a machine learning method, support vector machines (SVM), 
to develop the combinatorial SVM (COMBI-SVM) virtual screening (VS) tool for 
searching dual-target agents NETSRIs, 5HT1aSRIs, 5HT1bSRIs,  H3SRIs, 
5HT2cSRIs, MC4SRIs and NK1SRIs. In Chapter 4, COMBI-SVM has been 
tested as dual-kinase inhibitor VS tools with reasonably good yields, target 
selectivity and low false-hit rates in searching large compound libraries (105). 
Hence, it is time to apply COMBI-SVM to search the dual-target antidepressant 
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agents NETSRIs, H3SRIs, 5HT1aSRIs, 5HT1bSRIs, 5HT2cSRIs, MC4SRIs and 
NK1SRIs from large compound libraries. 
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Figure 5-1 Examples of multi-target multi-target serotonin reuptake inhibitors; NETSRI=dual serotonin reuptake and noradrenaline 
reuptake inhibitor; NEDASRI= serotonin, dopamine, and noradrenaline reuptake inhibitor; 5HT1ASRI: dual serotonin reuptake inhibitor/5-
HT1A ; NK1SRI=dual serotonin reuptake inhibitor/neurokinin 1 receptor antagonist; MC4SRI=dual serotonin reuptake 
inhibitor/melanocortin 4 receptor antagonist.
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5.2 Materials and Methods 
5.2.1 Data collection and molecular descriptors 
Individual-target and dual-target inhibitors, each with IC50 or Ki value ≤10µM, 
were collected from the literature (247, 248, 251), and the ChEMBL (266) and 
BindingDB (125) databases. The collected individual-target inhibitors include 
1125-1951 SSRIs, 1410 noradrenaline reuptake inhibitors (NRIs), 1689 H3 
receptor antagonists (H3Antags), 1144 5-HT1A receptor antagonists 
(5HT1aAntags), 917 5-HT1B receptor antagonists (5HT1bAntags), 1234 5-HT2C 
receptor antagonists (5HT2cAntags), 1721 melanocortin 4 receptor antagonists 
(MC4Antags) and 1787 neurokinin 1 receptor antagonists (NK1Antags). The 
collected dual inhibitors are 101 dual serotonin reuptake/noradrenaline reuptake 
inhibitors (NETSRIs), 147 dual serotonin reuptake inhibitor/H3 receptor 
antagonists (H3SRIs), 216 dual serotonin reuptake inhibitor/5-HT1A receptor 
antagonists (5HT1aSRIs), 57 dual serotonin reuptake inhibitor/5-HT1B receptor 
antagonists (5HT1bSRIs), 27 dual serotonin reuptake inhibitor/5-HT2C receptor 
antagonists (5HT2cSRIs), 6 dual serotonin reuptake inhibitor/melanocortin 4 
receptor antagonists (MC4SRIs) and 45 dual serotonin reuptake 
inhibitor/neurokinin 1 receptor antagonists (NK1SRIs), Table 5-1 summarises the 
datasets of these individual-target inhibitors, dual-inhibitors and MDDR 
compounds similar to at least one dual-inhibitor for each the target pair used as 
the training and testing sets in this work. Figure 5-1 illustrates the composition of 
the collected dual-inhibitors of the seven studied. 
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As few non-inhibitors have been reported, putative non-inhibitors of each target 
were generated by using our published method that requires no knowledge of 
inactive compounds or active compounds of other target classes and enables more 
expanded coverage of the “non-inhibitor” chemical space (29, 102). First, 17 
million PubChem and 168 thousand MDDR compounds were clustered into 8,993 
compound families of similar molecular descriptors (267), which are consistent 
with the reported 12,800 compound-occupying neurons (regions of topologically 
close structures) for 26.4 million compounds of up to 11 atoms (268), and 2,851 
clusters for 171,045 natural products (269).  
 
The putative non-inhibitors for each target were extracted from those families (5-
8 per family) that contain no known individual-target inhibitors. The specific 
numbers of putative non-inhibitors are 60726-62593 from 7590-8018 families for 
SERT, 61957 from 7937 families for NET, 61960 from 7937 families for H3 
receptor, 62376 from 7991 families for 5-HT1A receptor, 64790 from 8114 
families for 5HT1B receptor, 61912 from 7739 families for 5-HT2C receptor, 
63807 from 7976 families for MC4 receptor and 62733 from 7842 families for 
NK1 receptor. This approach has the risk of the wrong exclusion of the compound 
families that contain multi-target inhibitors and undiscovered individual-target 
inhibitors from the non-inhibitor training dataset. The maximum possible “wrong” 
classification rate arising from these mistakes has been estimated at <13% even in 
the extreme and unlikely cases that all of the undiscovered single-target and 
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multi-target agents are misplaced into the non-inhibitor class (102), (103). The 
noise level generated by up to 13% “wrong” negative compound family 
representation is expected to be substantially smaller than the maximum 50% 
false-negative noise level tolerated by SVM (270). 
 
We used the 98 descriptors which include 18 descriptors in the class of simple 
molecular properties, 3 descriptors in the class of chemical properties, 35 
descriptors in the class of molecular connectivity and shape, 42 descriptors in the 
class of electro-topological state. These descriptors are described in Chapter 2 
Section 2.2.1. This set of descriptors has been selected in our previous studies for 
representing diverse structural and physicochemical properties of both inhibitors 
of a specific target and non-inhibitors of that target distributed in large chemical 
space defined by 13.56 million Pubchem compounds (Chapter 4). Although the 
structures of inhibitors of one target can be very different from those of another 
target, each inhibitor set plus the representatives of the non-inhibitors cover the 
same chemical space defined by the 13.56 million Pubchem compounds. 
Therefore, the same set of molecular descriptors was used in this work as well as 
our previous works. The virtual screening models of vastly different biochemical 
classes (kinases, GPCR agonists/antagonists, peptidase inhibitors, DHFR 
inhibitors, and HDAC inhibitors) developed by this same descriptor set have 
shown equally good performance in screening large chemical libraries (102, 103, 
105) (160).
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Table 5-1 Datasets of individual-target inhibitors, dual inhibitors and MDDR compounds similar to at least one dual inhibitor used as the 
training and testingsets in this work 
 
Target 
Pair  Inhibitors in Training Sets Inhibitors and Other Compounds in Testing Set 
Target A – 
Target B  
Training Set for Target A Training Set for Target B Multi-Target Agents of Target A and B 
Inhibitors 










of A and B 
No of 
inhibitors of 
A that are 
non-inhibitor 
of B (No of 
families) 
No of  
these 
inhibitors 




















of B that 
are non-
inhibitor of 
A (No of 
families) 
No of  
these 
inhibitors 






No of these 
inhibitors 




agents of A 




agents of A 
and B (No 
of families) 
No (%) of 
multi-target 





A in training 
sets  
No (%) of 
multi-target 




of B in training 
sets 
No (%) of 
multi-target 
agents outside 
the families that 
contain single-
target inhibitor 
of A or B in 
training sets 





SERT-NET  1125(405) 399(124) 113(33) 1410(486) 471(124) 176(42) 101(73) 65(64.3%) 46(45.5%) 25 (24.8%) 8389 8181 
SERT-H3  1804(604) 366(95) 39(16) 1689(486) 345(95) 124(28) 147(56) 97(65.9%) 53(36.1%) 27 (18.4%) 8191 1486 
SERT-5HT1A  1679(590) 512(130) 121(26) 1144(432) 421(130) 151(26) 216 (71) 130 (60.2%) 120 (55.6%) 52 (24.1%) 8354 7349 
SERT-5HT1B  1894(631) 514(108) 164(22) 917(309) 424(108) 93(11) 57(35) 21(41.2%) 42(73.7%) 14 (24.6%) 8688 7475 
SERT-5HT2C 1924(631) 689(145) 28(10) 1234(493) 405(145) 36(9) 27(23) 10(37.0%) 13(48.1%) 10(37.0%) 8426 1302 
SERT-MC4 1951(644) 175(61) 2(2) 1721(248) 557(61) 2(2) 6(2) 6(100%) 6(100%) 0 8164 7 
SERT-NK1 1910(631) 262(69) 39(8) 1787(358) 219(69) 62(8) 45(23) 29(64.4%) 9(20%) 9(20%) 8110 275 
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Figure 5-2 The Venn graph of the collected 7 evaluated dual-inhibitors pairs and 
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5.2.2 Computational models 
SVM is based on the structural risk minimization principle of statistical learning 
theory (132). It consistently shows outstanding classification performance; It is 
less penalized by sample redundancy; It has lower risk for overfitting; It is 
capable of accommodating large and structurally diverse training and testing 
datasets, and is fast in performing classification tasks (134, 135). However, like 
all machine learning methods, the performance of SVM is critically dependent on 
the diversity of training datasets. Because of the limited knowledge of known 
inhibitors for many targets, sufficiently good SVM VS tools may not be readily 
developed for these targets. Nonetheless, SVM VS tools with comparable 
performances or partially improved performances in certain aspects (e.g. reduced 
false-hit rates at comparable inhibitor yield) are useful to complement other VS 
tools. The performance of SVM in predicting non-dual inhibitors was evaluated 
by 5-fold cross-validation test. For each target pair, non-dual inhibitors and non-
inhibitors were randomly divided into 5 groups of approximately equal size, with 
4 groups used for training a SVM VS tool and 1 group used for testing it, and the 
test process is repeated for all 5 possible compositions to derive an average VS 
performance. After the 5-fold cross-validation, the σ values are chosen in the 
range of 0.9-5 based on the average VS performance for the model development. 
Table 5-2 shows the results of the 5-fold cross validation of SVM VS models for 
the target pairs SERT-NET, SERT-H3, SERT-5HT1A, SERT-5HT1B, SERT-
5HT2C, SERT-MC4 and SERT-NK1. As for margin C, the SVM VS models were 
Chapter 5 The Application of Combinatorial Machine Learning Methods in 





developed by using a hard margin c=100,000. A hard margin has been proven to 
provide well with a more sensitive and strict classification for unbalanced datasets 
in which the negative data outnumbered the positive ones (263)(36, 37) (43) (47). 
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Table 5-2 5-fold cross-validation of SVM models for parameter selection and 
additional tests of these models for predicting dual-inhibitors and non-inhibitors; 
SEN: sensitivity, SPE: specificity, AC: overall accuracy, AVE: average; SD: 
standard deviation, SEM: standard error of means 
Target 
Pair 
5-fold C.V.Performance for parameter selection 









SEN SPE AC SEN SPE AC SEN SPE SPE 
1 84% 99.8% 99.5% 90% 99.8% 99.6% 48% 88% 81% 
2 91% 99.8% 99.7% 90% 99.7% 99.5% 48% 86% 77% 
3 89% 99.7% 99.5% 88% 99.7% 99.5% 45% 86% 81% 
4 85% 99.8% 99.5% 89% 99.7% 99.4% 43% 84% 83% 
5 87% 99.8% 99.6% 88% 99.8% 99.5% 48% 85% 82% 
AVE 87% 99.8% 99.6% 89% 100% 99% 46% 86% 81% 
S.D 0.025 0.000 0.001 0.010 0.000 0.000 0.02 0.02 0.02 








SEN SPE AC SEN SPE AC SEN SPE SPE 
1 93% 99.5% 99.3% 92% 99.8% 99.6% 17% 85% 100% 
2 89% 99.6% 99.3% 93% 99.7% 99.5% 31% 80% 100% 
3 88% 99.6% 99.3% 93% 99.7% 99.5% 25% 77% 100% 
4 89% 99.6% 99.3% 93% 99.7% 99.5% 24% 84% 100% 
5 86% 99.5% 99.1% 92% 99.7% 99.5% 19% 87% 100% 
AVE 89% 99.6% 99% 93% 99.7% 99.5% 23% 82% 100% 
S.D 0.025 0.001 0.001 0.006 0.000 0.000 0.06 0.04 1.00 











SEN SPE AC SEN SPE AC SEN SPE SPE 
1 99.7% 99.7% 99.4% 88% 99.8% 99.6% 48% 86% 74% 
2 99.6% 99.6% 99.3% 83% 99.8% 99.4% 45% 79% 74% 
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3 99.5% 99.5% 99.2% 86% 99.7% 99.5% 44% 85% 74% 
4 99.7% 99.7% 99.3% 86% 99.8% 99.5% 45% 89% 77% 
5 99.7% 99.7% 99.4% 84% 99.8% 99.5% 45% 89% 82% 
AVE 99.7% 99.7% 99% 85% 99.8% 99.5% 45% 86% 76% 
S.D 0.001 0.001 0.001 0.021 0.000 0.001 0.01 0.04 0.04 











SEN SPE AC SEN SPE AC SEN SPE SPE 
1 84% 99.98% 99.7% 85% 99.8% 99.6% 23% 98% 99% 
2 82% 99.98% 99.7% 85% 99.8% 99.6% 19% 98% 91% 
3 78% 99.95% 99.5% 80% 99.8% 99.6% 23% 98% 96% 
4 81% 99.96% 99.6% 85% 99.8% 99.6% 23% 97% 92% 
5 80% 99.97% 99.6% 83% 99.9% 99.6% 23% 97% 93% 
AVE 81% 99.97% 99.6% 84% 99.8% 99.6% 22% 98% 94% 
S.D 0.024 0.0001 0.001 0.023 0.000 0.000 0.018 0.004 0.03 











SEN SPE AC SEN SPE AC SEN SPE SPE 
1 86.8% 99.5% 99.2% 91.4% 99.7% 99.3% 22% 75% 89% 
2 89.4% 99.6% 99.3% 90.6% 99.7% 99.3% 26% 84% 88% 
3 90.1% 99.6% 99.3% 90.6% 99.7% 99.4% 15% 81% 88% 
4 88.8% 99.6% 99.3% 94.1% 99.8% 99.3% 15% 82% 88% 
5 92.4% 99.6% 99.4% 98.0% 99.8% 99.4% 15% 81% 95% 
AVE 90% 99.6% 99% 92.9% 99.7% 99.3% 20% 81% 90% 
S.D 0.021 0.000 0.001 0.032 0.0006 0.0003 0.05 0.03 0.028 









SEN SPE AC SEN SPE AC SEN SPE SPE 
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1 89.3% 99.5% 99.2% 97.4% 100.0% 99.9% 83% 94% 95% 
2 92.6% 99.5% 99.3% 98.3% 99.9% 99.9% 83% 93% 91% 
3 92.1% 99.5% 99.3% 98.3% 99.9% 99.9% 67% 91% 92% 
4 92.8% 99.6% 99.4% 98.3% 99.9% 99.9% 67% 91% 94% 
5 87.7% 99.6% 99.2% 97.1% 99.9% 99.8% 67% 91% 93% 
AVE 91% 99.5% 99% 98% 99.9% 99.9% 73% 92% 93% 
S.D 0.023 0.000 0.001 0.006 0.000 0.000 0.09 0.01 0.02 









SEN SPE AC SEN SPE AC SEN SPE SPE 
1 87.4% 99.5% 99.1% 93.6% 99.8% 93.6% 36% 88% 91% 
2 89.8% 99.6% 99.3% 95.5% 99.8% 95.5% 40% 88% 93% 
3 89.5% 99.5% 99.2% 96.6% 99.8% 96.6% 40% 90% 93% 
4 91.4% 99.5% 99.2% 95.0% 99.8% 95.0% 38% 86% 93% 
5 87.7% 99.6% 99.3% 95.2% 99.8% 95.2% 38% 88% 93% 
AVE 89% 99.5% 99% 95% 99.8% 95.2% 38% 88% 93% 
S.D 0.016 0.001 0.001 0.011 0.000 0.011 0.02 0.02 0.01 
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Figure 5-3 The COMBI-
5-fold cross-validation where the training set is randomly divided into 5 sub sets 
and in turns 4 sets are used for training and 1 set for testing to choose the best 
parameters for model construction. 







-target Antidepressant Agents 
 
SVMs diagram. Individual SVM models are built after 
Virtual hits simultaneously selected by all 
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5.3 Results and Discussion 
5.3.1 Individual target inhibitors and dual inhibitors of the 
studied target pairs 
As shown in Table 5-1, high percentages of the known dual inhibitors of the 
seven studied target pairs are distributed in the compound families containing 
individual target inhibitor of at least one target in the target pair. Only 18.4%-
37.0% of the known dual inhibitors are not in the compound families of the 
known individual target inhibitors.  Nonetheless, dual inhibitors have some 
features distinguished from those of individual target inhibitors, which are partly 
exhibited from the top-ranked scaffolds contained in higher percentages of dual 
inhibitors of the studied target pairs (Figure 5-3). Table 5-3 gives the distribution 
of some of these scaffolds in the dual inhibitors of the studied target pairs and 
inhibitors of individual targets of these target pairs.  Scaffolds A, B, C, D, E, F 
and G are contained in high percentages of dual inhibitors.  Specifically, scaffold 
A is contained in 21.8% of the 101 NETSRIs, scaffold B in 17.7% of the 147 
H3SRIs, scaffold C in 14.8% of the 216 5HT1aSRIs, scaffold D in 14.8% of the 
27 5HT2cSRIs, scaffold E in 100% of the 6 MC4SRIs, and scaffold F and G in 
44.4% and 33.3% of the 45 NK1SRIs, whereas these scaffolds are contained in 
single-digit percentages or less of the inhibitors of other target pairs and the 
individual target inhibitors of the specific target-pairs.  Known 5HT1bSRIs 
appear to be distributed in many scaffolds each containing no more than three 
compounds. Nonetheless, some specific variations of side-chain groups of these 
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and other scaffolds found in the known 5HT1bSRIs as well as known NETSRIs, 
H3SRIs and 5HT1aSRIs appear to be sufficient to convert individual target 
inhibitors into dual inhibitors. Moreover, physicochemical properties as well as 
structural features are also important for distinguishing individual target inhibitors 
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Figure 5-4 Top-ranked molecular scaffolds primarily found in known multi-target serotonin reuptake inhibitors; Scaffold A, B and C are 
distributed in significantly higher percentage of known multi-target NETSRIs, H3SRIs, and 5HT1aSRIs than known “individual-target”  
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Table 5-3 Distribution of the top-ranked scaffolds in multi-target inhibitors of the 7 target pairs SERT-NET, SERT-H3, SERT-5HT1A, 




Percent of inhibitors in dataset 
containing scaffold 
Scaffold A Scaffold B Scaffold C Scaffold D Scaffold E Scaffold F Scaffold G 
SERT-
NET 
Multi-target  NETSRIs 21.8(22/101) 0(0/101) 3(3/101) 1.0(1/101) 0(0/101) 0(0/101) 0(0/101) 
NET reuptake inhibitors inactive against SERT 0.07(1/1410) 0(0/1410) 0(0/1410) 3.0(43/1410) 0.6(8/1410) 0(0/1410) 0(0/1410) 
SERT reuptake inhibitors inactive against NET 2(23/1125) 2.1(24/1125) 1.7(24/1125) 0.4(5/1125) 0(0/1125) 0.2(2/1125) 1.3(15/1125) 
SERT-
H3 
Multi-target  H3SRIs 0(0/147) 17.7(26/147) 0(0/147) 0(0/147) 0(0/147) 0(0/147) 0(0/147) 
H3 receptor antagonists inactive against SERT 0(0/1689) 0(0/1689) 0.4(6/1689) 0(0/1689) 0(0/1689) 0(0/1689) 0(0/1689) 
SERT reuptake inhibitors inactive against H3 receptors 1.5(27/1804) 0(0/1804) 1.3(24/1804) 1.8(32/1804) 0(0/1804) 1.0(18/1804) 0.9(16/1804) 
SERT-
5HT1A 
Multi-target 5HT1aSRIs 0(0/216) 0(0/216) 14.8(32/216) 0(0/216) 0(0/216) 0(0/216) 0(0/216) 
5HT1A receptor antagonists inactive against SERT 4.8(55/1144) 0(0/1144) 1.4(16/1144) 0(0/1144) 0(0/1144) 0(0/1144) 0(0/1144) 
SERT reuptake inhibitors inactive against 5HT1A receptors 1.3(21/1679) 1.5(26/1678) 0.8(13/1679) 1.8(31/1679) 0(0/1679) 1.1(18/1679) 0.9(15/1679) 
SERT-
5HT1B 
Multi-target 5HT1bSRIs 1.8(1/57) 0(0/57) 7(4/57) 5.3(3/57) 0(0/57) 0(0/57) 0(0/57) 
5HT1B receptor antagonists inactive against SERT 0(0/917) 0(0/917) 0.3(3/917) 0(0/917) 0(0/917) 0(0/917) 0(0/917) 
SERT reuptake inhibitors inactive against 5HT1B receptors 1.4(26/1894) 1.4(26/1894) 1.1(20/1894) 1.4(26/1894) 0(0/1894) 1.0(18/1894) 0.8(15/1894) 
SERT-
5HT2C 
Multi-target 5HT2cSRIs 3.7(1/27) 0(0/27) 3.7(1/27) 14.8(4/27) 0(0/27) 0(0/27) 0(0/27) 
5HT2C receptor antagonists inactive against SERT 1.6(20/1234) 0(0/1234) (3/1234) 0(0/1234) 0(0/1234) 0(0/1234) 0(0/1234) 
SERT reuptake inhibitors inactive against 5HT2C receptors 0(0/1924) 0(0/1924) 1.2(23/1924) 1.5(29/1924) 0(0/1924) 0.9(18/1924) 0.7(13/1924) 
SERT-
MC4 
Multi-target MC4SRIs 0(0/6) 0(0/6) 0(0/6) 0(0/6) 100%(6/6) 0(0/6) 0(0/6) 
MC4 receptor antagonists inactive against SERT 0(0/1721) 0(0/1721) 0(0/1721) 0(0/1721) 2.5(43/1721) 0(0/1721) 0(0/1721) 
SERT reuptake inhibitors inactive against MC4 receptors 0(0/1951) 0(0/1951) 1.2(23/1951) 1.6(31/1951) 0(0/1951) 0.9(18/1951) 0.8(15/1951) 
SERT-
NK1 
Multi-target NK1SRIs 0(0/45) 0(0/45) 0(0/45) 0(0/45) 0(0/45) 44.4(20/45) 33.3(15/45) 
NK1 receptor antagonists inactive against SERT 0.2(4/1787) 0(0/1787) 0(0/1787) 0(0/1787) 0(0/1787) 0.06(1/1787) 0(0/1787) 
SERT reuptake inhibitors inactive against NK1 receptors 0.1(2/1910) 0(0/1910) (20/1910) 1.0(33/1910) 0(0/1910) 0.9(18/1910) 0.6(11/1910) 
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5.3.2 5-fold cross-validation tests of SVM, k-NN and PNN models 
The parameters of the SVM, k-NN and PNN models were determined by 5-fold 
cross- validation studies of individual target inhibitors and putative non-inhibitors 
of each target pair. Additionally, each 5-fold cross-validation model was tested by 
dual target NETSRIs, H3SRIs, 5HT1aSRIs, 5HT1bSRIs, 5HT2cSRIs, MC4SRIs 
and NK1SRIs and real non-inhibitors of the individual target of each target pair. 
Non-inhibitors of a target refer to compounds with IC50 or Ki value >20µM.  The 
results of these tests for SVM, k-NN and PNN are shown in Table 5-3, 5-4 and 5-
5 respectively. The 5-fold cross-validation tests were measured by sensitivity, 
specificity and over all accuracy given as TP/(TP+FN), TN/(TN+FP) and 
TP+TN/(TP+TN+FP+FN) respectively in terms of the numbers of true positives 
TP (true inhibitors), true negatives TN (true non-inhibitors), false positives FP 
(false inhibitors), and false negatives FN (false non-inhibitors). Overall, the 
sensitivity of SVM, k-NN and PNN is in the range of 78.0%-99.8%, 79%-99.7% 
and 89%-99.7%, the specificity in the range of 99.4%-99.98%, 99%-99.98%, and 
95.1%-99.4%, and overall accuracy in the range of 93.6%-99.6%, 99.0%-99.98%, 
and 96.5%-99.3% respectively.  The dual inhibitor accuracy of SVM, k-NN and 
PNN are in the range of 15%-83%, 10%-83%, and 17%-58% respectively. The 
non-inhibitor prediction accuracy of SVM, k-NN and PNN are in the range of 
73%-100%, 62%-97% and 72%-89% respectively. Therefore, SVM showed 
comparable overall performance in these 5-fold cross-validation tests. 
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Table 5-4 5-fold cross-validation of k-NN models for parameter selection and 
additional tests of these models for predicting dual-inhibitors and non-inhibitors, 
SEN sensitivity, SPE specificity, AC overall accuracy, AVE average; SD standard 
deviation, and SEM standard  
error of means. 
Target 
Pair 





SERT  NET NETSRIs non-SSRIs non-NRIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 85% 99.60% 99% 89% 99.60% 99.30% 40% 83% 62% 
2 84% 99.60% 99% 88% 99.40% 99.20% 38% 89% 84% 
3 88% 99.60% 99% 86% 99.60% 99.30% 37% 89% 81% 
4 89% 99.60% 99% 87% 99.60% 99.30% 36% 80% 83% 
5 87% 99.60% 99% 91% 99.50% 99.30% 39% 85% 82% 
AVE 87% 99.60% 99% 88% 99.50% 99% 38% 85% 78% 
S.D 0.023 0 0 0.018 0.001 0.001 0.02 0.04 0.09 





SERT  H3 H3SRIs non-SSRIs non-H3Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 91% 99.50% 99.20% 93% 99.50% 99.40% 10% 85% 88% 
2 92% 99.40% 99.20% 92% 99.60% 99.40% 14% 80% 83% 
3 87% 99.30% 99.00% 92% 99.60% 99.40% 13% 77% 83% 
4 90% 99.50% 99.30% 93% 99.60% 99.50% 10% 84% 88% 
5 91% 99.40% 99.10% 91% 99.50% 99.30% 12% 87% 88% 
AVE 90% 99% 99% 92% 99.60% 99% 12% 82% 86% 
S.D 0.02 0.001 0.001 0.008 0.001 0.001 0.02 0.04 0.03 





SERT  5HT1a 5HT1aSRIs  non-SSRIs non-5HT1aIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 89.30% 99.50% 99.20% 85% 99.60% 99.40% 32% 83% 79% 
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2 89.30% 99.40% 99.10% 78% 99.50% 99.20% 33% 89% 81% 
3 90.80% 99.40% 99.20% 84% 99.60% 99.30% 34% 80% 82% 
4 93.80% 99.40% 99.30% 85% 99.60% 99.30% 36% 80% 78% 
5 89.60% 99.60% 99.30% 84% 99.60% 99.30% 35% 79% 82% 
AVE 91% 99% 99% 83% 99.60% 99% 34% 82% 80% 
S.D 0.019 0.001 0.001 0.029 0 0.001 0.01 0.04 0.02 





SERT  5HT1b  5HT1bSRIs non-SSRIs non-5HT1bIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 91% 99.50% 99.20% 84% 99.70% 99.50% 30% 82% 83% 
2 92% 99.30% 99.10% 86% 99.80% 99.60% 30% 86% 84% 
3 91% 99.40% 99.10% 86% 99.70% 99.50% 25% 82% 84% 
4 91% 99.40% 99.10% 82% 99.60% 99.40% 30% 88% 87% 
5 92% 99.30% 99.10% 83% 99.70% 99.40% 28% 88% 84% 
Average 91% 99% 99% 84% 99.70% 99% 28% 85% 84% 
S.D 0.006 0.001 0 0.019 0.001 0.001 0.02 0.03 0.01 





SERT  5HT2c 5HT2cSRIs non-SSRIs non-5HT2cIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 92.2% 99.4% 99.2% 86% 99% 99.2% 26% 88% 87% 
2 90.1% 99.3% 99.1% 85% 99.6% 99.3% 26% 87% 83% 
3 90.9% 99.3% 99.1% 82% 99% 99.1% 26% 86% 84% 
4 91.9% 99.3% 99.1% 79% 99.5% 99.2% 26% 88% 82% 
5 90.9% 99.4% 99.2% 81% 99.5% 99.2% 26% 87% 82% 
AVE 83% 99.5% 99% 83% 99.5% 99.2% 26% 87% 84% 
S.D 0.028 0.000 0.000 0.028 0.000 0.001 0.00 0.01 0.02 





SERT  MC4 MC4SRIs non-SSRIs non-MC4Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 89.8% 99.3% 99.0% 99.7% 99.98% 99.98% 17% 84% 95% 
2 91.3% 99.3% 99.1% 98.3% 99.7% 99.7% 17% 81% 90% 
3 92.8% 99.5% 99.3% 97.7% 99.8% 99.7% 17% 86% 90% 
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4 88.7% 99.4% 99.1% 98.0% 99.7% 99.7% 83% 84% 95% 
5 91.5% 99.4% 99.1% 99.1% 99.8% 99.7% 17% 83% 97% 
AVE 91% 99.4% 99% 98.5% 99.8% 99.8% 30.2% 84% 93.4% 
S.D 0.016 0.001 0.001 0.008 0.001 0.001 0.30 0.02 0.03 





SERT  NK1 NK1SRIs non-SSRIs non-NK1Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 91.4% 99.3% 99.1% 95.5% 99.7% 99.6% 20% 88% 81% 
2 92.7% 99.4% 99.2% 95.0% 99.5% 99.4% 24% 89% 82% 
3 91.6% 99.3% 99.1% 95.0% 99.6% 99.4% 22% 88% 85% 
4 90.3% 99.5% 99.2% 95.8% 99.6% 99.5% 20% 87% 85% 
5 89.3% 99.4% 99.1% 95.2% 99.5% 99.4% 20% 87% 85% 
AVE 91% 99.4% 99% 95% 99.6% 99% 21% 88% 84% 
S.D 0.013 0.001 0.001 0.004 0.001 0.001 0.02 0.01 0.02 
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Table 5-5 5-fold cross-validation of PNN models for parameter selection and 
additional tests of these models for predicting dual-inhibitors and non-inhibitors, 
SEN sensitivity, SPE specificity, AC overall accuracy, AVE average; SD standard 
deviation, and SEM standard error of means. 
Target 
Pair 
5-fold C.V.Performance for parameter selection 






SERT  NET NETSRIs non-SSRIs non-NRIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 94% 97.50% 97.50% 95% 97.00% 96.90% 58% 86% 80% 
2 94% 97.60% 97.50% 96% 96.60% 96.60% 57% 88% 79% 
3 95% 97.50% 97.50% 94% 97.00% 96.90% 50% 85% 76% 
4 94% 97.40% 97.30% 94% 96.90% 96.80% 55% 84% 72% 
5 93% 97.70% 97.60% 97% 96.90% 96.90% 55% 83% 76% 
AVE 94% 98% 98% 95% 97% 97% 55% 85% 77% 
S.D 0.005 0.001 0.001 0.013 0.002 0.002 0.03 0.02 0.03 





SERT  H3 H3SRIs non-SSRIs non-H3Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 96% 96.80% 96.80% 98% 97.50% 97.50% 40% 80% 90% 
2 96% 96.80% 96.80% 97% 97.70% 97.70% 39% 84% 84% 
3 94% 97.00% 96.90% 96% 97.80% 97.80% 41% 83% 84% 
4 96% 96.90% 96.90% 98% 97.70% 97.70% 34% 83% 84% 
5 96% 96.70% 96.60% 95% 97.90% 97.80% 37% 83% 84% 
AVE 96% 97% 97% 97% 98% 98% 38% 83% 85% 
S.D 0.011 0.001 0.001 0.014 0.002 0.001 0.03 0.01 0.03 





SERT  5HT1a 5HT1aSRIs  non-SSRIs 
non-
5HT1aIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 97.30% 97.00% 97.00% 93% 97.80% 97.70% 46% 85% 72% 
2 94.90% 96.60% 96.60% 91% 97.70% 97.60% 48% 82% 73% 
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3 96.40% 96.60% 96.60% 93% 97.50% 97.40% 45% 82% 71% 
4 97.30% 96.70% 96.70% 92% 97.40% 97.30% 49% 84% 72% 
5 97.30% 96.70% 96.70% 92% 97.70% 97.60% 46% 83% 73% 
AVE 97% 97% 97% 92% 98% 98% 47% 83% 72% 
S.D 0.01 0.002 0.002 0.009 0.002 0.002 0.02 0.02 0.01 





SERT  5HT1b  5HT1bSRIs non-SSRIs 
non-
5HT1bIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 98% 97.00% 97.10% 91% 98.00% 97.90% 44% 78% 83% 
2 96% 96.90% 96.90% 92% 98.40% 98.30% 35% 77% 82% 
3 96% 96.90% 96.90% 92% 98.40% 98.30% 39% 75% 82% 
4 96% 96.60% 96.50% 91% 98.20% 98.10% 47% 75% 83% 
5 97% 97.00% 97.00% 89% 98.20% 98.10% 46% 75% 81% 
AVE 97% 97% 97% 91% 98% 98% 42% 76% 82% 
S.D 0.011 0.002 0.002 0.016 0.002 0.002 0.05 0.01 0.01 





SERT  5HT2c 5HT2cSRIs non-SSRIs 
non-
5HT2cIs 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 96.1% 97.0% 97.0% 91% 97% 97.4% 33% 84% 84% 
2 98.7% 97.0% 97.0% 89% 97.2% 97.0% 33% 83% 85% 
3 95.8% 96.7% 96.7% 93% 97% 97.3% 30% 83% 84% 
4 98.2% 97.0% 97.0% 91% 97.0% 96.9% 30% 82% 87% 
5 96.4% 96.8% 96.8% 93% 97.1% 97.0% 33% 83% 84% 
AVE 91% 97.2% 97% 91% 97.2% 97.1% 32% 83% 85% 
S.D 0.016 0.002 0.001 0.016 0.002 0.002 0.02 0.01 0.01 





SERT  MC4 MC4SRIs non-SSRIs 
non-
MC4Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 96.2% 96.7% 96.7% 96.5% 99.4% 99.3% 33% 82% 89% 
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2 95.6% 97.0% 97.0% 98.5% 99.2% 99.2% 17% 82% 78% 
3 96.4% 97.0% 97.0% 98.5% 99.3% 99.3% 17% 81% 79% 
4 97.2% 96.4% 96.5% 98.8% 99.2% 99.1% 33% 82% 81% 
5 95.1% 97.1% 97.0% 99.7% 99.2% 99.3% 33% 82% 77% 
AVE 96% 96.9% 97% 98.4% 99.3% 99.2% 27% 82% 81% 
S.D 0.008 0.003 0.002 0.011  0.0007 0.0006 0.09 0.00 0.05 





SERT  NK1 NK1SRIs non-SSRIs 
non-
NK1Is 
SEN SPE AC SEN SPE AC SEN SPE SPE 
1 96.1% 96.8% 96.8% 97.2% 98.6% 98.6% 29% 83% 89% 
2 95.5% 97.1% 97.1% 96.9% 98.7% 98.6% 33% 83% 85% 
3 97.1% 96.7% 96.7% 98.6% 98.6% 98.6% 36% 83% 86% 
4 96.3% 96.8% 96.8% 97.8% 98.5% 98.5% 33% 82% 85% 
5 96.1% 96.9% 96.8% 98.0% 98.6% 98.6% 33% 83% 83% 
AVE 96% 96.9% 97% 98% 98.6% 99% 33% 83% 86% 
S.D 0.006 0.002 0.001 0.007 0.001 0.001 0.02 0.00 0.02 




5.3.3 Virtual screening performance of Combinatorial SVM in 
searching multi-target serotonin inhibitors from large compound 
libraries  
The VS performance of COMBI-SVM in identifying dual inhibitors of the seven 
target-pairs is summarized in Table 5-6 together with the similarity level 
(sequence identity) between the drug-binding domains of each pair.  Rost has 
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found that proteins with >40% sequence identity unambiguously distinguish 
similar and non-similar structures and the signal gets blurred in the twilight zone 
of 20–35% sequence identity (271). Thus, target-pairs can be classified into high, 
intermediate, and low similarity classes with their drug-binding domains at 
sequence identity levels of >40%, 20%-40% and <20% respectively. Based on 
this criterion, SERT-NET (72.3% sequence identity) is of high similarity, and the 
other six target-pairs (1.7%~15.1% sequence identity) are of low sequence 
similarity.  
 
In terms of the numbers of true positives TP (true inhibitors), true negatives TN 
(true non-inhibitors), false positives FP (false inhibitors), and false negatives FN 
(false non-inhibitors), the yield and false-hit rate are given by TP/(TP+FN) and 
FP/(TP+FP) respectively. The dual inhibitor yields are 49.5% for NETSRIs, 
25.9% for H3SRIs, 47.7% for 5HT1aSRIs, and 22.8% for 5HT1bSRIs, 22.0% for 
5HT2cSRIs, 83.3% for MC4SRIs and 31.1% for NK1SRIs respectively.  
Therefore, COMBI-SVMs showed reasonably good capability in identifying dual 
inhibitors of the seven evaluated target pairs without explicit knowledge of dual 
inhibitors. Target selectivity was tested by using COMBI-SVM to screen the 917-
1951 individual-target inhibitors of each target-pair, which misidentified 22.4% 
and 29.8% of the individual target inhibitors as dual inhibitors for the SERT-NET 
pair, 5.4% and 8.2% for SERT-H3, 15.4% and 19.4% for SERT-5HT1A, 13.8% 
and 12.3% for SERT-5HT1B, 14.2% and 12.4% for SERT-5HT2C, 2.2% and 8.0% 
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for SERT-MC4 and 4.2% and 6.3% for SERT-NK1 respectively. Therefore, 
COMBI-SVM is reasonably selective in distinguishing multi-target inhibitors 
from individual-target inhibitors of the same target pair.   
 
The misidentification of a substantial percentage of individual target inhibitors as 
dual inhibitors could have been caused by the similar reasons discussed in 
Chapter 4.3.1.  
 
Target selectivity was further tested by using COMBI-SVM to screen the 8110-
8688 (Table 5-1) inhibitors of the other six targets outside a given target-pair with 
the results summarised in Table 5-6. We found that 2.4%, 3.5%, 7.1%, 0.95%, 
4.0%, 0.58%, and 1.16% of the inhibitors of the other six targets were 
misclassified as NETSRIs, H3SRIs, 5HT1aSRIs, 5HT1bSRIs, 5HT2cSRIs, 
MC4SRIs and NK1SRIs respectively. These data showed that COMBI-SVM is 
fairly selective in separating multi-target inhibitors of specific target pair from 
antidepressant inhibitors of other targets outside the target pair.  
 
Virtual hit rates and false-hit rates of COMBI-SVM in screening compounds that 
resemble the structural and physicochemical properties of the training datasets 
were evaluated by using 7-8181 MDDR compounds (Table 5-1) similar to a 
multi-target inhibitor of each target pair. Similarity was defined by Tanimoto 
similarity coefficient ≥0.9 between a MDDR compound and its closest dual 
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inhibitor (102). As shown in Table 5-6, COMBI-SVM identified 81, 3, 256, 249, 
66, 1 and 1 virtual-hit(s) from 8181, 1486, 7349, 7475, 1302, 7 and 275 MDDR 
compounds similar to NETSRI, H3SRI, 5HT1aSRI, 5HT1bSRI, 5HT2cSRI, 
MC4RI and NK1SRI respectively.  Disregarding the target-pairs with only 1 
MDDR virtual-hits (which is statistically less meaningful for estimating virtual hit 
rates), the virtual hit rates in selecting MDDR compounds similar to the dual-
inhibitors are in the range of 0.2%~5.1%. As majority of the MDDR compounds 
similar to the known dual inhibitors are expected to be non-inhibitors for the 
target pairs, these virtual hit rates can be considered as the upper limit of the false-
hit rates.  
 
Significantly lower virtual hit rates and thus false-hit rates were found in 
screening large libraries of 168,000 MDDR and 17 million PubChem compounds.  
As shown in Table 5-6, the numbers of multi-target virtual hits (virtual hit rate) in 
screening 168,000 MDDR compounds are 201 (0.12%) for NETSRIs, 112 
(0.067%) for H3SRIs, 464 (0.28%) for 5HT1aSRIs, 241 (0.14%) for 5HT1bSRIs, 
353 (0.21%) for 5HT2cSRIs, 70 (0.042%) for MC4SRIs and 92 (0.055%) for 
NK1SRIs respectively. The numbers of multi-target virtual hits (virtual hit rate) in 
screening 17 million PubChem compounds are 6,305 (0.035%) for NETSRIs, 
4,993 (0.028%) for H3SRIs, 9,603 (0.054%) for 5HT1aSRIs, 6,326 (0.011%) for 
5HT1bSRIs, 7574 (0.042%) for 5HT2cSRIs, 1252 (0.007%) for MC4SRIs and 
1136 (0.006%) for NK1SRIs respectively. Substantial percentages of the MDDR 
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virtual-hits belong to the classes of antidepressant, anxiolytic, antimigraine, and 
antipsychotic (Table 5-7, details in the next section), some of which may be true 
multi-target serotonin inhibitors. Therefore, the true false-hits rates of the 
COMBI-SVM are likely smaller than the computed rates, i.e., the false-hit rates of 
COMBI-SVM are ≤0.2%-4.0%, ≤0.042%-0.28% and ≤0.011%-0.054% in 
screening MDDR similarity compounds, all MDDR compounds, and PubChem 
compounds respectively. These rates are similar to the false-hit rates of ≤1.4%-
9.4%, ≤0.057%-0.104%, and ≤0.013%-0.036% in COMBI-SVM screening of 
multi-target kinase inhibitors from MDDR and PUBCHEM compounds (105). 
These rates are also comparable and sometime better than the false-hit rates of 
0.02%-0.37% and 0.05%-0.35% produced by other machine learning methods and 
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Table 5-6 The virtual screening performance of combinatorial SVMs for identifying multi-target serotonin inhibitors of the seven target 
pairs SERT-NET, SERT-H3, SERT-5HT1A, SERT-5HT1B, SERT-5HT2C, SERT-MC4 and SERT-NK1; The target-pairs in this table are 
arranged with decreasing similarity level between their drug-binding domains. There are only 7 MDDR compounds similar to a dual-
inhibitor of SERT-MC4, the corresponding virtual hit rate was thus un-computed because the small number of compounds may not provide 
statistically meaningful test of the SVM performance.  
 
Target Pair Virtual Screening Performance 





Inhibitors of individual target of 
the target pair inactive against 
another target of the target pair 
Inhibitors of other 
three targets 
outside the target 
pair 
MDDR compounds 
similar to multi-target 


















of target A 
False hit rate for 
inhibitors of target 
B 
False hit rate Virtual hit rate (No of 
virtual hits)  
Virtual hit rate 
(No of virtual 
hits) 
Virtual hit rate 
(No of virtual 
hits) 
SERT-NET (72.3%) 49.50% 8 (7.9%) 22.40% 29.80% 2.40% 0.99% (81) 0.12% (201) 0.035% (6305) 
SERT-5HT1B (15.1%) 22.8% 2 (3.5%) 13.80% 12.30% 0.95% 2.5% (185) 0.14% (241) 0.011% (6326) 
SERT-MC4 (11.7%) 83.33% 0 2.20% 8.02% 0.58% - 0.042%(70) 0.007%(1252) 
SERT-NK1 (9.6%) 31.11% 13(28.9%) 4.20% 6.30% 1.16% 0.36%(1) 0.055%(92) 0.006%(1136) 
SERT-5HT1A (8%) 47.70% 12 (5.6%) 15.40% 19.40% 7.10% 3.5% (256) 0.28% (464) 0.054% (9603) 
SERT-5HT2C (3.2%) 22.0% 5(18.5%) 14.24% 12.40% 4.0% 4.0%(52) 0.21%(353) 0.042%(7574) 
SERT-H3 (1.7%) 25.90% 7 (4.8%) 5.40% 8.20% 3.50% 0.2% (3) 0.067% (112) 0.028% (4993) 
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Table 5-7 MDDR classes in which higher percentage (≥5%) of COMBI-SVM 





MDDR class that contains higher 
percentage of these virtual hits 
Number (percentage) of 
COMBI-SVM identified 
multi-target virtual-hits in 
class 
Percentage of MDDR class 
members as virtual hits 
SERT-NET 
(201) 
Antidepressant 56 (27.9%) 0.91% 
5-HT Reuptake Inhibitor 36 (17.9%) 3.68% 
Dopamine Reuptake Inhibitor 28 (13.9%) 14.29% 
Antipsychotic 25 (12.4%) 0.48% 
Norepinephrine Uptake Inhibitor 20 (10.0%) 6.33% 
Treatment of Cocaine Dependency 20 (10.0%) 25.97% 
Anxiolytic 15 (7.5%) 0.22% 
Calcium Channel Blocker 15 (7.5%) 0.88% 
Antimigraine 14 (7.0%) 0.81% 
Analgesic, Non-Opioid 13 (6.5%) 0.27% 
SERT-H3 (112) 
Antidepressant 30 (26.8%) 0.49% 
Antipsychotic 23 (20.5%) 0.44% 
Analgesic, Non-Opioid 13 (11.6%) 0.27% 
5-HT Reuptake Inhibitor 10 (8.9%) 1.02% 
Anxiolytic 10 (8.9%) 0.15% 
Cognition Disorders, Agent for 10 (8.9%) 0.13% 
Antiparkinsonian 9 (8.0%) 0.48% 
Anticonvulsant 8 (7.1%) 0.26% 
Antifungal 7 (6.3%) 0.24% 
Chapter 5 The Application of Combinatorial Machine Learning Methods in 






Calcium Channel Blocker 7 (6.3%) 0.41% 
SERT-5HT1A 
(464) 
Antidepressant 177 (38.1%) 11.91% 
Antimigraine 118 (25.4%) 2.27% 
Antipsychotic 113 (24.3%) 1.67% 
5-HT1D receptor Agonist 100 (21.6%) 10.21% 
Anxiolytic 62 (13.4%) 3.58% 
5-HT Reuptake Inhibitor 49 (10.6%) 8.52% 
5-HT1A receptor Agonist 48 (10.3%) 4.66% 
5 HT2A Antagonist 47 (10.1%) 7.40% 
Dopamine (D4) Antagonist 26 (5.6%) 8.05% 
Analgesic, Non-Opioid 25 (5.4%) 3.63% 
SERT-5HT1B 
(241) 
Antidepressant 82 (34.0%) 1.33% 
Antimigraine 76 (31.5%) 4.39% 
5-HT1D receptor Agonist 63 (26.1%) 9.62% 
5-HT reuptake Inhibitor 53(22.0%) 5.41% 
Antipsychotic 47(19.5%) 0.9% 
Anxiolytic 44(18.32%) 0.65% 
5-HT2A receptor Antagonist 25 (10.4%) 3.63% 
5-HT1Areceptor Agonist 21 (8.7%) 2.0% 
Dopamine (D4) Antagonist 15 (6.2%) 2.23% 
 
5-HT1A receptor Antagonist 13(5.4%) 2.26% 
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MDDR class that contains higher 
percentage of these virtual hits 
Number (percentage) of 
COMBI-SVM identified 
multi-target virtual-hits in 
class 
Percentage of MDDR class 
members as virtual hits 
SERT-5HT2C 
(353) 
Antipsychotic 126 (5.7%) 2.42% 
Antidepressant 99 (28.0%) 1.60% 
Anxiolytic 76 (21.5%) 1.12% 
5-HT2A receptor Antagonist 46 (13.0%) 6.68% 
Antimigraine 36 (10.2%) 2.08% 
5-HT1A receptor Agonist 34 (9.6%) 3.30% 
Dopamine (D4) Antagonist 32(9.1%) 4.75% 
5-HT Reuptake Inhibitor 24(6.8%) 2.45% 
Antiparkinsonian 22 (6.2%) 1.16% 
5-HT1D  agent Agonist 22 (6.2%) 1.16% 
Antihypertensive 21(5.9%) 0.19% 
Antiallergic/Antiasthmatic 18(5.1%) 0.17% 
Cognition Disorders, Agent for 18(5.1%) 0.24% 
SERT-MC4(70) 
Antidepressant 15(21.4%) 0.24% 
Anti-allergic/Anti-asthmatic 15(21.4%) 0.14% 
Anxiolytic 13(18.6%) 0.19% 
Neurokinin NK2 Antagonist 9(12.9%) 2.16% 
Neurokinin NK3 Antagonist 8(11.4%) 4.40% 
Antipsychotic 7(10.0%) 0.13% 
Substance P Antagonist 7(10.0%) 0.40% 
Antiviral (AIDS) 5(7.1%) 0.11% 
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Analgesic, Non-Opioid 4(5.7%) 0.08% 
Cognition Disorders, Agent for 4(5.7%) 0.05% 
5-HT Reuptake Inhibitor 4(5.7%) 0.41% 
Anti-arthritic 4(5.7%) 0.03% 
SERT-NK1(92) 
Substance P Antagonist 23(25.0%) 1.31% 
Antidepressant 18(19.6%) 0.29% 
Anxiolytic 15(16.3%) 0.22% 
Antipsychotic 11(12.0%) 0.21% 
Antiallergic/Antiasthmatic 11(12.0%) 0.10% 
5-HT Reuptake Inhibitor 11(12.0%) 1.12% 
Analgesic, Non-Opioid 10(10.9%) 0.20% 
Neurokinin NK2 Antagonist 9(9.8%) 2.16% 
Calcium Channel Blocker 9(9.8%) 0.53% 
5-HT1A receptor Agonist 6(6.5%) 0.58% 
Antihypertensive 6(6.5%) 0.05% 
Antianginal 6(6.5%) 0.18% 
Adrenergic (beta) Blocker 6(6.5%) 2.76% 
Antiarrhythmic 5(5.4%) 0.19% 
Anti-inflammatory 5(5.4%) 0.09% 
Neurokinin Antagonist 5(5.4%) 3.73% 
Cognition Disorders, Agent for 5(5.4%) 0.07% 
5-HT1A receptor Antagonist 5(5.4%) 0.87% 
Antiviral (AIDS) 5(5.4%) 0.11% 
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5.3.4 Virtual screening performance of Combinatorial SVM in 
searching multi-target serotonin inhibitors from large compound 
libraries  
COMBI-SVM identified MDDR virtual hits were evaluated based on the known 
biological or therapeutic target classes specified in MDDR. Table 5-7 gives the 
MDDR classes in which higher percentage (≥5%) of COMBI-SVM identified 
MDDR dual inhibitor virtual hits are distributed. We found that 15-177 (21.4%-
38.1%), 10-76 (7.5%-21.5%), and 4-53 (5.7%-22.0%) of the 70-464 dual-inhibitor 
virtual hits of the seven target-pairs belong to the antidepressant, anxiolytic and 
5HT reuptake inhibitor class respectively. It is noted that serotonin reuptake 
inhibitors have been used as antidepressant and anxiolytic agents (95). Therefore, 
some of the COMBI-SVM virtual hits are either known SSRIs or have the same 
therapeutic actions of SSRIs, which were misidentified as dual inhibitors by 
COMBI-SVM partly because it has 2.2%-22.4% false-hit rates in misclassifying 
SSRIs as dual inhibitors of the seven target pairs (Table 5-6). Moreover, 20 
(10.0%) of the 201 SERT-NET dual inhibitor virtual hits belong to the 
norepinephrine uptake inhibitor class. While some of these virtual hits might be 
true SERT-NET dual inhibitors, most of these individual target NET inhibitors 
were falsely selected as dual inhibitors by COMBI-SVM at 6.33% false-hit rate 
(Table 5-7).  
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We found that 118 (25.5%), 76 (31.5%), 36 (10.2%) and 14 (7.0%) MDDR 
virtual hits for SERT-5HT1A, SERT-5HT1B, SERT-5HT2C and SERT-NET belong 
to the antimigraine class respectively. Serotonin has been implicated in migraine 
pathophysiology with a low 5-HT state facilitating activation of the 
trigeminovascular nociceptive pathway (272). Because serotonin is primarily 
reduced by SERT (240), serotonin reuptake inhibitors may in some circumstances 
have antimigraine effect in certain patients (273). Some of the MDDR 
antimigraine virtual hits may be selected by COMBI-SVM partly because they are 
SERT inhibitors (COMBI-SVMs select individual-target inhibitors as dual-target 
serotonin reuptake inhibitors at 2.2%-29.8% false-hit rates based on the statistics 
in Table 5-6). Moreover, 25-113 (11.4%-24.3%) MDDR virtual hits of six target 
pairs (SERT-NET, SERT-H3, SERT-5HT1B, SERT-5HT2C, SERT-MC4 and 
SERT-NK1) belong to the antipsychotic class. Some antipsychotic drugs show 
certain level of activity against serotonin reuptakes and 5-HT receptors (274).  It 
is further noted that serotonin reuptake inhibitors augment and synergize with 
antipsychotic drugs hence serotonin reuptake inhibitors have been used in 
combination with antipsychotic drugs in the treatment of some psychiatric 
disorders (275).  Hence, some of the antipsychotic MDDR virtual hits may be 
selected because they have these activities.  
 
An additional set of 87-100 (21.6%-21.7%), 38-48 (9.5%-10.3%) and 36-47 
(9.0%-10.1%) dual inhibitor virtual hits of the SERT-5HT1A and SERT-5HT1B 
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target pairs belong to the 5-HT1D receptor agonist, 5-HT1A receptor agonist, and 
5-HT2A receptor antagonist classes respectively.  As discussed below, some of 
these MDDR 5-HT1D receptor agonist, 5-HT1A receptor agonist, and 5-HT2A 
receptor antagonist virtual hits were falsely selected by COMBI-SVM possibly 
because they have some level of structural similarity to 5-HT1A receptor 
antagonists or 5-HT1B receptor antagonists. Analogues of certain scaffolds have 
been found to bind to both 5-HT1A and 5-HT1D receptors with weak partial agonist 
activity in cloned receptor and antagonistic activity in in-vitro studies (276). Some 
compounds such as BMY 7378 can act as both 5-HT1A agonist and antagonist 
depending on the location of 5-HT1A. BMY 7378 shows agonist activity at 5-
HT1A autoreceptors and act as antagonists or show partial agonist activity at 
postsynaptic 5-HT1A receptors (277). Both mixed 5-HT1A and 5-HT2A receptor 
antagonists and 5-HT1A receptor agonists have been derived from the same 
scaffolds (278).  The human 5-HT1B and 5-HT1D receptors are significantly 
similar in sequence despite being encoded by two distinct genes, and some dual 
5HT1B/1D receptor antagonists show substantial degree of structural similarity to 
dual 5HT1B/1D agonists (279). Some analogs of specific scaffolds are mixed 5-
HT1B and 5-HT2A receptor antagonists (280). Moreover, some compounds have 
been reported to have dual 5-HT1A receptor agonist and serotonin reuptake 
inhibitory activities (281). It is possible that some of the MDDR 5-HT1A receptor 
agonist virtual hits were selected by the COMBI-SVM of SERT-5HT1B target pair 
because they have serotonin reuptake inhibitory activity which may be falsely 
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recognized as multi-target 5HT1bSRIs by COMBI-SVM at 13.8% false-hit rate 
based on the statistics in Table 5-6. 
 
 
5.3.5 Analysis of MDDR virtual hits of combinatorial SVM 
At present, the 3D structure is unavailable for  the eight targets considered in this 
work (serotonin transporter, noradrenaline transporter, H3 receptor, 5-HT1A 
receptor, 5-HT1B receptor, 5-HT2C receptor, NK1 receptor and MC4 receptor). 
Only some of their homologous proteins or other members from the same GPCR 
families, such as H1 receptor, have 3D structure information available (282, 283). 
While these structures give important insights into functional mechanism and 
allow the modelling of ligand binding to the eight evaluated targets, the modelled 
and homologous structures may not provide the most appropriate structural 
platforms as those of high-resolution crystal structures for fair comparison of the 
VS performance of COMBI-SVM with molecular docking methods. We therefore 
only compared the VS performance of COMBI-SVMs with three VS methods, 
i.e., similarity searching (284), k-NN (285), and PNN (286), by using the common 
testing datasets composed of 6~216 dual inhibitors of the seven evaluated target 
pairs, 917-1951 individual target inhibitors of the same target pairs, 8110-8688 
inhibitors of the other six target pairs outside a given target pair, and 168,000 
MDDR compounds respectively.  Similarity searching was conducted against 
known multi-target inhibitors of each target pair. The training datasets of k-NN 
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and PNN and the methods for estimating the yield and virtual hit rate are the same 
as those of SVM.  
 
Table 5-8 shows the comparison of the performance of COMBI-SVM with the 
other three VS methods for identifying multi-target inhibitors of the seven target-
pairs from the four common testing datasets. Overall, the dual-inhibitor yields of 
all VS methods are comparable, mostly in the ranges of 20%~83% for the seven 
target-pairs with the exception of k-NN for SERT-NK1 (7.7%) and similarity 
searching for SERT-5HT2c (11.1%). Compared to COMBI-SVM, k-NN produced 
comparable false-hit rates, and similarity searching and PNN produced slightly 
higher false-hit rates in misidentifying individual-target inhibitors of the same 
target-pair and inhibitors of the other six target pairs outside a target pair as dual-
inhibitors 
 
The false-hit rates of the similarity searching method may be significantly 
reduced by adjusting the similarity cut-off values for individual targets, which 
may however lead to significantly reduced yields.  The higher false-hit rates likely 
arise in part from the difficulty in establishing optimal molecular similarity 
threshold values that correlate with biological activity, and in separating active 
and inactive close analogs of reference molecules (287). Data fusion and group 
fusion approaches may be explored to conduct multiple similarity searches using 
different sets of molecular representations, similarity measure and parameters 
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followed by the combination of the resulting search outputs to give a single fused 
output (288), (289). The higher false-hit rates may also arise from the bias linked 
to molecular complexity and size, i.e., reference molecules of increasing size 
generate systematically higher Tanimoto coefficient values in database searching 
(290).  This bias may be partly reduced by exploring bit density reduction 
methods (290), complexity-independent molecular representations (290) and 
complexity-independent similarity metrics (290). 
  
In screening the MDDR compounds, COMBI-SVM produced slightly to 
substantially lower virtual hit rates (0.042%~0.28%) than those of similarity 
searching (2.81%-8.2%), k-NN (0.15%-0.83%) and PNN (0.93%-3.4%) in 
identifying the MDDR compounds as dual inhibitor virtual hits of the evaluated 
target pairs. The numbers of MDDR compounds in the antidepressant and 5-HT 
reuptake inhibitor classes are 6182 and 979 respectively. It is expected that no 
more than half of the MDDR antidepressant compounds are SSRIs. Therefore, the 
total number of labelled and unlabelled SSRIs in MDDR can be crudely estimated 
as ~1000-3000, most likely significantly less than 3000. Assuming that the ratio 
of the dual-target serotonin reuptake inhibitors against SSRIs in MDDR is 
roughly similar to those of known dual-target serotonin reuptake inhibitors against 
SSRIs which are 9.0% (101 vs. 1125) for NETSRIs, 8.2% (147 vs. 1804) for 
H3SRIs, 12.9% (216 vs. 1679) for 5HT1aSRIs,  3.0% (57 vs. 1894) for 
5HT1bSRIs, 1.4% (27 vs. 1924) for 5HT2cSRIs, 0.3% (6 vs. 1951) for MC4SRIs 
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and 2.4% (45 vs. 1910) for NK1SRIs. Then the numbers of dual-target serotonin 
reuptake inhibitors in MDDR can be crudely estimated as ~3-380 (1000×0.3% - 
3000×12.9%), most likely significantly less than 380. Therefore the numbers of 
COMBI-SVM identified MDDR dual inhibitor virtual hits of the evaluated target 
pairs (70-464) are consistent to the crudely estimated numbers of dual inhibitors 
in MDDR than the identified numbers from the other three methods (971-12,698). 
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Table 5-8 Comparison of the performance of combinatorial SVMs with other virtual screening methods for identifying multi-target 
inhibitors of the four target pairs 
Virtual Screening 
Performance Measure Method 
Virtual Screening Performance for Target pair 
SERT-NET SERT-H3 SERT-5HT1A SERT-5HT1B SERT-5HT2C SERT-MC4 SERT-NK1 
Yield of Multi-Target 
Inhibitors of Target pair 
SVM 49.50% 25.90% 47.70% 22.8% 22% 83.33% 31.11% 
Similarity Searching 53.50% 20.40% 63.90% 40.40% 11.11% 33.3% 48.89% 
k-NN 59.40% 10.90% 34.30% 31.60% 18.52% 16.7% 6.67% 
PNN 57.40% 38.10% 45.40% 45.60% 33.33% 66.7% 20.00% 
False-Hit Rate for 
“Individual-Target” 
Inhibitors of  the Same 
Target pair 
SVM 22.4%-29.8% 5.4%-8.2% 15.4%-19.4% 13.8%-12.3% 14.24%-12.4% 2.2%-8.02% 4.2%-6.3% 
Similarity Searching 46.5%-42.4% 35.6%-21.8% 28.6%-46.9% 28.6%-65.4% 19.4%-13.6% 8.5%-26.3% 17.7%-16.0% 
k-NN 19.8%-25.1% 9%-8.5% 16.6%-24.3% 14.1%-32.6% 15.0%-16.3% 3.1%-11.5% 4.5%-4.9% 
PNN 38.4%-52.3% 22.2%-25.5% 34.3%-38.9% 30.3%-4.7% 34.8%-31.8% 6.6%-27.9% 11.8%-9.8% 
False-Hit Rate for 
Inhibitors of the Other 
Six Targets Outside the 
Target pair 
SVM 2.40% 3.50% 7.10% 0.95% 4.0% 0.58% 1.16% 
Similarity Searching 15.90% 20.50% 24.10% 11.60% 10.6% 5.0% 8.4% 
k-NN 3.00% 3.50% 9.30% 5.20% 4.2% 1.2% 2.9% 
PNN 16.90% 13.50% 24.20% 10.80% 14.2% 0.37% 8.8% 
Virtual Hit Rate for 
168,000 MDDR 
Compounds 
SVM 0.12% 0.067% 0.28% 0.14% 0.21% 0.042% 0.055% 
Similarity Searching 6.80% 8.20% 7.60% 7.60% 3.81% 3.26% 3.54% 
k-NN 0.58% 0.41% 0.83% 0.75% 0.52% 0.15% 0.81% 
PNN 3.14% 2.35% 3.40% 2.83% 3.90% 0.93% 2.24% 
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5.4 Conclusion  
In-silico methods have been increasingly explored for facilitating multi-target 
drug discovery, and shown promising potential in identifying selective multi-
target agents. In Chapter 4, I explored and discussed their application in 
discovering multi-target kinase inhibitors as the preliminary tests of the 
performances of combinatorial machine learning methods and promising results 
were obtained. Therefore, this chapter was the application of those methods  and 
it further suggested that combinatorial SVM VS tools developed from individual 
target inhibitors are capable of identifying dual target serotonin reuptake 
inhibitors at comparably good yields and low false-hit rates, and in some cases 
substantially lower false-hit rates than some of the other VS tools in screening 
large chemical libraries. COMBI-SVMs, in combination with other methods, may 
be useful for facilitating the search of novel multi-target antidepressants by 
screening larger chemical libraries. With more knowledge of newly discovered 
selective multi-target agents from the current and future drug discovery efforts 
(291, 292), COMBI-SVMs and other in-silico methods will have opportunities for 
enhanced performances. Further improvement of the algorithms and parameters of 
VS methods (103, 293-298) also enhance their capability and application range in 
facilitating multi-target drug discovery. Moreover, the introduction of more 
comprehensive elements of distinguished structural and physicochemical features 
of selective multi-target agents and multi-target activity and binding site profiles 
enable the development of more effective and relevant tools for the identification 
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of selective multi-target agents as well as active compounds against an individual 
target.   
 




Chapter 6 Concluding Remarks 
Multi-target agents have become a new and promising trend in the treatment for 
many diseases due to their improvement in efficacy and the averting of side 
effects. The focus of the thesis work was to assist the discovery of multi-target 
agents. This study was divided into two big compartments. The first part consisted 
of the construction and updates of the two chemoinformatics databases Kinetics 
Database of Biomolecular Interactions (KDBI) and Therapeutic Target Database 
(TTD) (Chapter 3). The second one discussed the application of virtual screening 
methods in discovery of two different systems, kinase inhibitors which perform as 
a major drug class and antidepressants, which are very important drug class 
especially in the modern societies where major depression has been empowered 
by the stresses (Chapter 4 and Chapter 5). This last chapter summarizes the 
major contributions and findings of this study (section 6.1). Section 6.2 discusses 
the limitations and presents suggestions for future studies. 
6.1 Major Findings and Merits 
6.1.1 Merits of the updates of KDBI and TTD in facilitating multi-
target drug discovery 
The kinetic information of biomolecular interactions plays the key factor in the 
quantitative investigation of the components of cellular networks and their 
interactions. They can promote the studies of cellular functions and interactions 
on a system level. Pathway studies are found especially interesting in 
understanding the mechanisms behind complex diseases which usually involve 





interactions within or between diseases related pathways. On the other hand, a 
better understating of those mechanisms offers the theoretic foundation and 
guidance for the discovery of chemical agents that can improve the drug efficacy 
by acting on multiple targets. Therefore, the update of (KDBI) of pathway 
interaction kinetic information can greatly enhance the usefulness of KDBI. It is 
also found that together with this improvement, other factors such as the manual 
annotation, presentation and speed of database opening, cross-referencing to other 
databases, and the inclusion of critical information that could significantly 
increase the speed of their research of other researchers can greatly improve the 
quality of databases.  Another merit of the updates of KDBI is data integration of 
the simulating models by Systems Biology Markup Language (SBML).  Systems 
biology is characterized by synergistic integration of theory, computational 
modeling, and experiment (299). Nowadays, there is a proliferation of research 
institutions that produce sources of huge amounts of biological data derived from 
experimentation with biological systems and construct numerous stimulating 
models based on those data. Therefore, it is in great demand for a common format 
for describing models in the exchange models between different simulation and 
analysis tools. SMBL hence is developed as an exchange format used by different 
present-day software tools to communicate the essential aspects of a 
computational model (300). The integration of SBML into the simulation models 
data of KDBI hence can bring great convenience for users with different software 
in system biology simulation and studies. 





Therapeutic   target database (TTD) was a pioneer for providing pharmaceutical 
information on therapeutic target and it has become a very functional tool to 
facilitate drug target studies. After its update in 2010 (4), major improvements 
and updates have been made to TTD. The information coverage has significantly 
increased from 1,894 targets and 5,028 drugs to 2,025 targets and 17,816 drugs 
plus 3,681multi-target agents. Table 6-1 summarizes the statistics of the current 
TTD version.  The new features added are the highlights of the update of TTD 
this time. These new features include (1) target validation information, 
quantitative structure activity relationship (QSAR) models for active compounds; 
(2) multi-target agents data with structure and potency information; (3) drug 
combinations; (4) nature-derived drugs together with drug species origin data. 
Therefore, informative and comprehensive information has been integrated to this 
version of TTD. It has become a very reliable, informative, useful, 





























Clinical trial 286 










Small molecules 14,170 
Antisense drugs 652 
Other 
coverage 
Protein biochemical class 61 
Drug therapeutic class 140 
New features 
Quantitative structure-activity relationship (QSAR) models 
Target 
validation 
Drug potency against target 
Drug action against disease model 
Effect of target knockout, knockdown or genetic variations 
Drug 
combinations 
Pharmacodynamically synergistic 72 
Pharmacodynamically additive 14 
Pharmacodynamically antagonist  4 
Pharmacokinetically potentiative 19 





Clinical trial 369 
Preclinical  119 
 
6.1.2 Findings of combinatorial machine learning methods for 
virtual screening in the multi-target kinase inhibitors and 
antidepressant agents  
Machine learning (ML) methods have been broadly applied as virtual screening 
tools due to their capability of high-CPU speed and the ability to cover highly 
diverse spectrum of compounds. However, while presenting equally good hit 
selection performance in screening extremely-large and large libraries, the 





currently developed machine learning tools have the tendency for lower hit-rate 
and, in some cases, lower enrichment factor than the best performing structure 
based virtual screening tools.  
 
To improve the performance of one of the most popular ML method support 
vector machine (SVM), diverse inactive compounds apart from the known 
inactive compounds and active compounds of other biological target classes were 
used as negative data in training sets in this work. It was achieved by generating 
putative inactive compounds by the in-house programs. An advantage of this 
approach is that it is independent on the knowledge of known inactive compounds 
and active compounds of other biological target classes. This enables more 
extended coverage of the “inactive” chemical space compared to when only the 
limited knowledge of inactive compounds and compounds of other biological 
classes are used. In the virtual screening for active compounds in large libraries 
such as PubChem and MDDR, the hit-rates of the methods used in this work are 
comparable and the enrichment factors are substantially better than the best 
results of other VS tools. And the usage of putative negatives contributes to it. 
This method greatly increased the performance of VS without losing much 
positive accuracy.  This showed that a fulfilled presentation in the chemical space 
can provide improvement of machine learning methods in virtual screening, 
although some noises could be introduced with the generation of putative inactive 
compounds. 





In this work, combinatorial support vector machines (COMBI-SVMs) were tested 
as VS tools for searching dual-inhibitors of 7 combinations of 6 anticancer kinase 
targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck) and 7 combinations of 8 
antidepressant target (serotonin transporter, noradrenaline transporter, H3 
receptor, 5-HT1A receptor, 5-HT1B receptor, 5-HT2C receptor, melancortin 4 
receptor and neurokinin 1 receptor). COMBI-SVMs Models were fairly selective 
in misidentifying as dual-inhibitors of the non-dual inhibitors of the same kinase-
pairs and produced low false-hit rates in misidentifying as dual-inhibitors of 
PubChem and MDDR databases. The performance of COMBI-SVM was 
compared with DOCK, k-NN and PNN methods. COMBI-SVM VS tools showed 
good capability in identifying dual-inhibitors of several anticancer target kinase-
pairs at comparable and in many cases substantially lower false-hit rates.  In the 
studies of multi-target antidepressants, COMBI-SVMs showed moderate to 
relatively good target selectivity in misclassifying as dual of the individual target 
inhibitors of the same target pair and of the other 6 targets outside the target pair. 
COMBI-SVMs showed low dual inhibitor false hit rates in screening 17 million 
PubChem compounds, 168,000 MDDR compounds, and 7-8,181 MDDR 
compounds similar to the dual inhibitors. Compared with similarity searching, k-
NN and PNN methods, COMBI-SVM produced comparable dual inhibitor yields, 
similar target selectivity, and lower false hit rate in screening 168,000 MDDR 
compounds. 
 





Comparing the performances of COMBI-SVMs in virtual screening multi-target 
agents in anticancer kinase target combinations and in multi-target antidepressant 
agents, I found that the sequence similarity could affect the selectivity of COMBI-
SVMs against the same target pair. Table 6-2 shows the target selectivity as the 
false hit rate of misidentifying the other target pair as dual inhibitor in a target 
pair and dual inhibitor yield of each pair in the 4 kinase pairs and 7 antidepressant 
pairs. It is found that generally, there seems to be a tendency that the higher the 
sequence identity of the target pair is, the lower the target selectivity tends to be 
but the higher the dual yield tends to be. The dual inhibitor yield of target pair 
SERT-MC4 is excluded because very few dual inhibitors (only 6) could be found 
for testing and the result might not be so valid statistically.  
 
Table 6-2 Target pair (sequence identity) and the false hit rate for inhibitor pairs 
and their dual inhibitor yields 
Target pair (sequence identity) 
False hit rate 
for inhibitors 
of target A 
False hit rate 
for inhibitors 
of target B 
Average 
false hit 





SERT-NET (72.3%) 22.40% 29.80% 26.1% 49.50% 
Src-Lck (67.6%) 15.80% 18.70% 17.3% 48.20% 
EGFR-Src(37.4%) 12.90% 11.10% 12.0% 26.80% 
EGFR-FGFR (33.2%) 10.10% 8.70% 9.4% 40.90% 
VEGFR-Lck (32.7%) 6.60% 29.20% 17.9% 52.60% 
SERT-5HT1B (15.1%) 13.80% 12.30% 13.1% 22.80% 
SERT-MC4 (11.7%) 2.20% 8.02% 5.1% - 
SERT-NK1 (9.6%) 4.20% 6.30% 5.3% 31.11% 
SERT-5HT1A (8%) 15.40% 19.40% 17.4% 47.70% 
SERT-5HT2C (3.2%) 14.24% 12.40% 13.3% 22.00% 
SERT-H3 (1.7%) 5.40% 8.20% 6.8% 25.90% 




6.2 Limitations and Suggestions for the Future Studies 
The work for updates of KDBI and TTD has few limitations due to the data 
availability and the methods used in the development of databases. The 
information abundance of a database is limited to the current availability of 
accessible chemoinformatics data. On the other hand, new findings and results in 
chemoinformatics fields have been proliferating. Therefore, it is suggested to stay 
in tone with the latest findings in systems biology, therapeutic target research and 
drug discovery and constantly update the data collection in the two databases. 
Hence continuous efforts are required to maintain the quality and quantity of 
useful and comprehensive databases such as KDBI and TTD. Moreover for 
KDBI, its server is currently running on IIS 5.0 web server which has limitation in 
the processing of requests (maximum 10 requests at a time).  Therefore, future 
improvement in the requests can be done by upgrading the system. In KDBI, the 
SBML file for pathway simulation model is created based on Java API of SBML 
version 2.4. The system biology related software which process SBML file may 
not support lower version of SBML after their upgrading. Then the SBML file 
downloaded from KDBI will not open in that particular software. In these 
situations, users are advised to edit these SBML file using some SBML editor.   
 
In my study, I applied the generation of putative negatives for the machine 
learning methods application. This approach requires a classification of the 
chemical space which has always been a difficult task in chemoinformatics. The 
classification of the chemical space needs a clustering method, a distance matrix 





selection and descriptors. K-means clustering method was used in this work. It is 
not the best clustering method but is suitable and computable for large chemical 
spaces. In future studies, more advanced clustering algorithm can be developed 
for improving the accuracy of chemical space clustering. Additionally, the 
selection of correlation coefficients and other chemical descriptors such as 
fingerprint can also help the improvement. Another possible drawback associated 
with the putative negatives generation approach is the possible inclusion of some 
undiscovered active compounds in the “inactive” class. This may hinder the 
identification of novel active compounds by machine learning methods. However, 
such an adverse effect is expected to be relatively small for many biological target 
classes.  
 
As for the virtual screening (VS) for multi-target agents, the support vector 
machine (SVM) is a robust but not a perfect machine learning method. The SVM 
models developed using the putative negative dataset have been proven to be able 
to improve the false hit rates. However, there are still some false hits that cannot 
be excluded easily. These false hits are selected as positive agents by the SVM 
models mostly due to the structural framework similarities with the actual active 
compounds. This could be caused by the molecular descriptors used in the SVM 
models in that they are insufficient to adequately differentiate the compounds 
with similar structural frameworks. In order to solve this problem, it is necessary 
to test different combinations of descriptors and apply optimal sets of descriptors 
by using more refined feature selection algorithms and parameters in future work. 





Besides, the integration of new descriptors may help appropriate representations 
of compounds. Therefore, it is encouraging to employ new descriptors in the 
model constructions. 
 
The increase of positive compounds number in the model construction means a 
better representation of the positive agents in the chemical space. Hence, the 
capability of the combinatorial SVMs in identifying multi-kinase inhibitors and 
the antidepressant multi-target agents can be further enhanced by more data 
availability in the VS tool development processes. With the development of 
selective multi-target agents discovery from the current and future drug discovery 
efforts, it is possible to introduce more comprehensive elements of distinguished 
structural and physicochemical features of selective multi-target agents into the 
training of combinatorial VS tools for more effective identification of selective 
multi-target agents. 
 
There is no conclusive answer to which VS approach is the best. Both ligand 
based and structural based methods have their own advantages and drawbacks. 
Therefore, the choice of one or another depends on the specific case faced by the 
medicinal chemist. In terms of performance, ligand based methods have the 
advantage of better enrichment factors and higher speed serving  and they are 
more efficient in removing non active compounds; structure based methods 
provide  a more direct view of the interactions between the ligand and molecular 
target and it has an advantage for the detecting of novel structures. Nowadays a 





synergistic, rational, synthetic combination of different approaches has become a 
trend. The combined VS approaches aims to firstly include less costly approaches, 
usually ligand based VS, at the first stage and apply the most demanding methods, 
such as docking, for the last stage when the original large compound library has 
been reduced to a manageable size after the previous stage. 
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